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After human DNA was first defined in 1953, the parallel science
of assisted reproductive technology achieved a successful human
birth through in vitro fertilization in 1978. Science then went on
to facilitate gestational surrogacy, banking human reproductive
materials, such as embryos, and greater opportunities for couples
and individuals to become parents. Fertility clinics were
established throughout the world to help persons and couples
achieve parenthood, contributing to a steady increase in babies
born through assisted reproductive means. Gradually, both
federal and state laws in the United States were enacted to collect
data from the fertility clinics, mandate insurance coverage of
assisted reproductive procedures, prohibit funding for human
embryo research, and either forbid or enable surrogacy contracts.
Societal changes occurred, too, including marriage entitlement
for same-sex couples, a dramatic rise in the number of
nonmarital cohabitants, and the rapid pace of scientific
achievements related to human reproduction.
Throughout this evolutionary period there was a concomitant
increase in transnational scientific cooperation, illustrated by
international committees and treaties. By utilizing medical
tourism, individuals who could afford to do so imposed their own
medical needs on foreign scientific communities. The global
scientific community became increasingly aware that it was now
possible to edit both the human genome and a woman's egg to
eliminate mitochondrial disease. Both genome editing and
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mitochondrial replacement have the potential to eliminate serious
disease and vastly improve human society. Amidst this scientific
optimism, companies that are able to harness the power of new
technological achievements have opportunities for monetary
gains. However, there are also drawbacks which include the
ethical and moral concerns over possible misuse of human
materials; the opportunity to create designer babies; the unknown
ramifications upon the human germline; the lack of consent of
any resulting child; the disparity in the ability to pay for
treatment; and the impact on the racial, gender, and the physical
plurality existent in human society.
American legislation, illustrated by the federal Dickey-Wicker
Amendment and its regulatory system, and as evidenced by the
U.S. Department of Agriculture's Coordinated Framework, is
inattentive to the challenges posed by genome editing and
mitochondrial replacement. In addition, international treaties
and agreements are inapplicable to many countries and
ineffective to regulate the research of privately funded scientists.
For example, in spite of public condemnation, a baby boy was
born in Mexico in 2016 following mitochondrial replacement; in
2018 twin girls were born in China following genome editing.
This Article addresses the scientific opportunities and challenges
of recent developments precipitated by the immediacy of genome
editing and mitochondrial replacement. Although scientific
academies in the United States and the United Kingdom suggest
caution, transparency, and international scrutiny, science
advances at an accelerating pace. This Article suggests
immediate congressional involvement, an update to the federal
regulatory process, and clear coordination with international
scientific communities. Additionally, to safeguard the human
values involved, this Article suggests specific goals should apply
to the construction of a functional pathway that addresses the
human possibility and challenge in genome editing and
mitochondrial replacement.
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I. INTRODUCTION
Historically, human reproduction has occurred via sexualintercourse.' Today, there are expanding options of non-
sexual reproductive possibilities and enhancements. 2  These
developments utilize in vitro fertilization ("IVF"), gamete
donation, surrogacy, genome editing, mitochondrial replacement,
and banks of human gametes for future fertilization or
implantation, to list a few.' One court summarized today's human
reproduction options in these terms: "The inescapable reality is
that all manner of arrangements involving the donation of sperm
or eggs abound in contemporary society, many of them couched
in contracts or agreements of varying degrees of formality."' The
ascendency of individual human privacy, expressed as
reproductive autonomy, is enabled through scientific biological
advances. Justice Anthony Kennedy's 2003 conclusion illustrated
"that our laws and traditions in the past half century ... show an
emerging awareness that liberty gives substantial protection to
adult persons in deciding how to conduct their private lives in
matters pertaining to sex."' This liberty fuels options that science
provides with increasing alacrity.
Accelerating scientific advances, both domestically and
transnationally, illustrate the options now available to actualize
reproductive possibilities. It is now possible for a child to be born
with more than two genetic parents;' to avoid threatened disease
through editing the gene sequence of a defective embryo;7 and, as
1. Louise Brown, born in 1978, was the first baby born via in vitro fertilization.
Jillian Casey et al., Assisted Reproductive Technologies, 17 GEO.J. GENDER & L. 83, 86 (2016).
Previously, there were instances of artificial insemination, but they were rare. See Kara W.
Swanson, The Birth of the Sperm Bank, 71 ANNALS IOWA 241 (2012). By the mid to late
1980s, gestational surrogates were used in conjunction with IVF procedures. See Remah
Moustafa Kamel, Assisted Reproductive Technology After the Birth of Louise Brown, 14 J.
REPROD. & INFERTILITY 96, 99 (2013).
2. See Giuseppe Benagiano et al., Sex and Reproduction: An Evolving Relationship, 16
HUM. REPROD. UPDATE 96,98-99 (2010).
3. Casey et al., supra note 1, at 85.
4. Ferguson v. McKiernan, 940 A.2d 1236, 1245 (Pa. 2007) (holding that an oral
contract between a mother and a sperm donor that relinquished both visitation and child
support for resulting child was enforceable).
5. Lawrence v. Texas, 539 U.S. 558, 571-72 (2003).
6. See G. Owen Schaefer & Markus K. Labude, Genetic Affinity and the Right to 'Three-
Parent lVF', 34J. ASSISTED REPROD. & GENETICS 1577 (2017).
7. See Daryl F. Sas & Hannah Martin Lawrenz, CRISPR-Cas9: The Latest Fashion in
Designer Babies, 33 ETHICS & MED. 81 (2017); Joshua D. Seitz, Striking a Balance: Policy
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a result of gene editing, for a gene to be enhanced to meet a
parent's baby specifications, including physical or mental
characteristics.' Such a baby may be termed, for better or for
worse, a "designer baby."9
Because of the rapidity of medical advances and the
complexity of the procedures involved, comprehensive legislative
reaction to new science is absent on a national and a transnational
level.'o However, an absence of legislative pronouncements should
not be taken as an expression of public approval or disapproval,
but rather as a lack of engagement. The announcement of the
birth of genome-edited twins in China on November 29, 2018,"
prompted immediate discussion nationally and internationally.1 2
Commentators were concerned that the scientific procedures
available may affect human reproduction today and the genetic
composition of future human generations tomorrow.13 Our ability
to edit a human embryo may contribute to social and cultural
disparities and less diversity or may foist upon a future human
unwanted enhancements. Immediate action is warranted "to move
beyond thinking about the immediate consequences of using
genome editing [so as to] consider what a society in which such
techniques were widely available would be like." 14 This Article
argues that there is such an immediacy today and urges
congressional action to create a national pathway for public
involvement in the issues raised by genome editing. The pathway
Considerations for Human Germline Modification, 16 SANTA CLARA J. INT'L L. 60, 65-66
(2018) (listing the three means for preventing inherited diseases at the stage of embryo
development: (1) preimplantation genetic diagnosis, (2) mitochondrial replacement
transfer, and (3) human germline engineering).
8. Sas & Lawrenz, supra note 7, at 81.
9. See Ronald T. K. Pang & P. C. Ho, Designer Babies, 26 OBSTETRICs, GYNAECOLOGY
& REPROD. MED. 59 (2016).
10. See Patton v. Vanterpool, 806 S.E.2d 493, 497 (Ga. 2017) (enforcing a state
statute even though it was not intended to apply to current assisted reproductive
technology innovations).
11. See China's CRISPR Twins: A Time Line of News, MIT TECH. REV. (Feb. 22, 2019),
https://www.technologyreview.com/s/613007/chinas-crispr-twins-a-timeline-of-news.
12. See id.
13. David Cyranoski & Heidi Ledford, International Outcry over Genome-Edited Baby
Claim, 563 NATURE 607, 607-08 (2018).
14. NUFFIELD COUNCIL ON BIOETHICS, GENOME EDITING AND HUMAN
REPRODUCTION 52 (2018), http://nuffieldbioethics.org/wp-content/uploads/Genome-cd
iting-and-human-reproduction-FINAL-website.pdf [hereinafter NUFFIELD COUNCIL ON
BIOETHICS].
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suggested in this article, based on specific goals, will permit
national involvement and transnational cooperation.
This Article relies on several premises. First, reproductive
freedom and individual liberty are within the gamut of the rights
affecting genome editing. Human reproductive freedom involves
the liberty of the human individual and the liberty interest
garnered from legal precedents, mostly occurring in the past one-
hundred years but becoming increasingly ascendant.' 5 However,
the conduct of individual liberty is not unbridled. Certain private,
intimate conduct remains subject to public engagement through
the legislatures and ultimately the courts. The Constitution of the
United States remains the final word," but those interpreting the
Constitution must balance legislative priorities and personal
privacies to arrive at impartiality. The tension in this balance is
emphasized in dicta by the Supreme Court of the United States:
"We must. . . 'exercise the utmost care whenever we are asked to
break new ground' . . . lest the liberty protected by the Due
Process Clause be subtly transformed into the policy preferences
of the Members of this Court."' 7
However, when the Court does break new ground, such as
holding that the Constitution guarantees a right to same-sex
marriage,18 some object, arguing that public engagement-not the
Court's judicial opinions-provides the means by which liberty is
protected.19 This opinion is illustrated by Chief Justice Roberts's
dissent in Obergefell v. Hodges: "Our cases have consistently refused
to allow litigants to convert the shield provided by constitutional
liberties into a sword to demand positive entitlements from the
State.""o Thus, if the legislative process, as judged by the courts
and the Constitution, provides the parameters of individual liberty
15. See Raymond C. O'Brien, Obergefell's Impact on Functional Families, 66 CATH.
U.L. REv. 363, 371-97, 420-27 (2016) (analyzing constitutional decisions from 1965 to
present).
16. Nathan V. Herron, Compassion in Dying v. Washington: Assisted Suicide Is Not a
Constitutionally Protected Liberty Interest, 22J. CONTEMP. L. 183, 189-90 (1996) (explaining
that courts must look to the U.S. Constitution to evaluate protected liberty interests).
17. Washington v. Glucksberg, 521 U.S. 702, 720 (1997) (quoting Collins v. City of
Harker Heights, 503 U.S. 115, 125 (1992)).
18. See Obergefell v. Hodges, 135 S. CL 2584, 2604-05 (2015).
19. See, e.g., Bradley C. S. Watson, Reclaiming the Rule of Law after Obergefell, NAT'L
REV. (July 9, 2015, 8:00 AM), https://www.nationalreview.com/2015/07/same-sex-marr
iage-and-rule-law.
20. Obergefell, 135 S. Ct. at 2620 (Roberts, C.J., dissenting).
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in reproductive freedom, then persons and organizations must
prepare to engage with the issues of genome editing and
mitochondrial replacement. To create a functional, scientific
pathway, all voices must be respected in a context of transparency.
Transparency of discussion is another premise.
Undoubtedly, American public engagement on reproductive
liberties, embryos, and "playing God" will be factious. The British
grasped this fact in a report published in 2018. The British
Nuffield Council on Bioethics reported, to its astonishment, that
the United States is the most prolific country by far regarding
basic genome editing research."1 This fact seemed incongruous
with the deep divisions in America. The report stated:
The fact that this is possible in a country with deep
and immobilising moral division between liberalism
and Christian fundamentalism, and steeped in
permanent conflict over abortion rights that has
effectively evacuated any middle ground on which
to build a societal consensus, may be attributed to
the US constitution and its defence of civil rights
and liberties."
Transparency depends on public engagement, media
exposure, accurate information, and opportunities for those with
a substantial interest in the issues to provide informed opinions.
Portions of this Article identify the scientific challenges of newly
developed procedures involving genome editing and one of its
components, mitochondrial replacement. 23  These research
developments occurred neither overnight nor in a vacuum.
Rather, there has been and will continue to be a consistent
ascendency of assisted reproductive technology ("ART") in the
United States-a fact that will only accelerate as medical insurance
increasingly covers more procedures.
There is also an ascendant acceptance of assisted
reproduction among members of the public 24  which may
21. NUFFIELD COUNCIL ON BIOETHICS, supra note 14, at 109.
22. Id.
23. See Bob Zhao, Mitochondrial Replacement Therapy and the Regulation of Reproductive
Genetic Technologies in the United States, 15 DuKE L. & TECH. REV. 121, 121-22 (2017).
24. See Maryam Okhovati et al., Trends in Global Assisted Reproductive Technologies
Research: A Scientometrics Study, 7 ELECTRONIC PHYSICIAN 1597, 1597 (2015).
424 [Vol. 9:3
20191 GENOME EDITING AND MITOCHONDRIAL REPLACEMENT 425
contribute to a more transparent discussion of genome editing.
Discussion must contrast risk from benefit and current advantages
from long term consequences, all amidst the certainty that no
nation lives in isolation but in an international community of
discovery. Transparency also includes knowledge of other nation's
experiences. Any policy pertaining to ARTs must incorporate an
international perspective, both because of the availability of
foreign regulatory safe havens and because of the valuable insights
from foreign scientific and regulatory practice. The reality is that
both human genome editing and mitochondrial replacement are
here, the former in 2018 in China2 ' and the latter in 2016 in
Mexico.2 6
Moreover, genome editing and mitochondrial replacement
have the potential to impact future generations. Existing data
provide ample evidence that scientific development in human
reproduction may affect the human germline in ways that were
unanticipated only a few decades ago. 7 It is the unknown
parameters of any modification that provide the current risk:
This means that the modification may be passed on
via their gametes (egg or sperm) and is capable of
being inherited by descendants, potentially down an
indefinite number of future generations, until it is
lost through normal mechanisms of recombination
and segregation . . . or it is deliberately reversed
through further intervention, perhaps involving
genome editing, or simply through not having
children.2 8
Finally, this Article relies on an attitude of scientific
positivism, rejecting any fear of the unknown. Change based on
25. Statement from the Organizing Committee on Reported Human Embryo Genome Editing,
NAT'L AcADs. OF Scis., ENGINEERING, & MED. (Nov. 26, 2018), http://www8.nati
onalacademies.org/onpinews/newsitem.aspxRecordlD=11262018 ("[o]n the eve of the
Second International Summit on Human Genome Editing, [researchers] were informed
of the birth of twins in China whose embryonic genomes had been edited.").
26. Jessica Hamzelou, Exclusive: World's First Baby Born with New "3 Parent" Technique,
NEW SCIENTIST (Sept 15, 2016), https://www.newscientist.com/article/2107219-exclusive
-worlds-first-baby-born-with-new-3-parent-technique.
27. See NAT'L ACADS. OF SCIS., ENG'G, & MED., HUMAN GENOME EDITING: SCIENCE,
ETHICS, AND GOVERNANCE 111 (2017) [hereinafter HuMAN GENOME EDITING].
28. NUFFIELD COUNCIL ON BIOETHICS, supra note 14, at 88.
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scientific progress is not odious. Rather, scientific optimism
should and does prevail. Scientific achievements and new
technological breakthroughs made in the ART field are
increasingly viewed with optimism rather than reproach.2 ' The
rapidity of scientific possibilities, increased media attention,
acceptance of pluralism, and societal attitudes of autonomous
decision-making create a milieu of acceptance among an
increasing segment of the population.3 o The number of adults
utilizing fertility clinics evinces increasing public acceptance of
ART and demonstrates that with public acceptance comes newer
technologies and increased use.3 ' This acceptance ascendency is
complemented by greater insurance coverage of procedures and
greater commercialization opportunities for ART procedures. 32
Accepting these premises, this Article is further premised
on the idea that the legal process in the United States is not
engaged in a material manner with these issues. Thus, this Article
proposes Congress initiate an immediate inquiry into how to craft
a pathway to best balance the science associated with genome
editing and the existing values of the American population, shared
with other nations. Established parameters, such as the federal
Dickey-Wicker Amendment," the Coordinated Framework," and
regulatory structures of agencies, such as the Food and Drug
Administration ("FDA")," must be scrutinized for their ability to
manage science amidst the current challenges.
Acknowledging these four premises, this Article then
suggests that the following actions need to be part of the public
engagement. First, both the rapidity and the transnational
29. See, e.g., Julia D. Mahoney & Gil Siegal, Beyond Nature? Genomic Modification and
the Future of Humanity, 81 L. & CONTEMP. PROBS. 195, 197 (2018) ("Although human
germline editing entails risks, later generations will likely be better served if present day
decision makers embrace the Enlightenment principles of daring to know and harnessing
knowledge to improve human lives.").
30. See id. at 200, 202-03.
31. See id. at 213.
32. See e.g., Key Findings: Infertility Insurance Mandates and Use of Assisted Reproductive
Technology, CTRs. DISEASE CONTROL & PREVENTION (Apr. 1, 2016), https://www.cdc.gov/
art/key-findings/insurance.html.
33. Megan Kearl, Dickey-Wicker Amendment, 1996, EMBRYO PROJECT ENCYCLOPEDIA
(Aug. 27, 2010), http://cmbryo.asu.edu/handle/10776/2050.
34. Coordinated Framework, U.S. DEP'T AGRIC., https://www.aphis.usda.gov/aphis/o
urfocus/biotechnology/sa_regulations/ct-agency-framework roles.
35. U.S. FooD & DRUG ADMIN., https://www.fda.gov/AboutFDA/WhatWeDo/def
ault.htm#resonsibilities (last visited Mar. 9, 2019).
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opportunities presented by human genome editing demand an
immediacy to alert the public forum of the moral, ethical, and
practical issues involved. Second, scientific advancements should
be viewed with a sense of optimism, not as a threat, because
benefits will outweigh risks if there is sufficient public scrutiny of
both risks and benefits. Third, reproduction matters deserve
substantial respect because these issues relate to the individual
liberty of humans, both those living and those yet to be born.
There are justifiable limitations based on values when viewed
within a broad pluralistic community. Fourth, human gametes
(egg and sperm) are entitled to a "measure of respect"16 because
of their involvement in human procreation. So, too, does a
blastocyst, which is a preimplantation embryo or a human embryo
that is a "developing human individual from the time of
implantation to the end of the eighth week after conception, after
which stage it becomes known as a fetus.", 7 Human tissue is
entitled to a duty of beneficence in conjunction with respect."
Thus, any procedure involving human reproduction should, at a
minimum, "include concerns about diminishing the dignity of
humans and respect for their variety, failing to appreciate the
importance of the natural world, and a lack of humility about our
wisdom and powers of control when altering that world of the
people within it."" Admittedly, while the world is too pluralistic to
allow a single approach, public engagement must respect "a
variety of distinct, intersecting, and mutually supporting
considerations. "4
Words and phrases such as "measure of respect," "dignity,"
and "beneficence" remain elusive, subject to the cacophony of
religious, secular, ethical, and moral expressions throughout the
36. DEP'T OF HEALTH & Soc. SEC., REPORT OF THE COMMITEE OF INQUIRY INTO
HUMAN FERTILISATION AND EMBRYOLOGY 62 (1988).
37. HUMAN GENOME EDITING, supra note 27, at 296.
38. Id. at 31-32 (citing the 1979 Belmont Report of the National Commission for the
Protection of Human Subjects in Biomedical and Behavioral Research, which "focused on
avoiding infliction of harm, accepting a duty of beneficence, and maintaining a
commitment to justice").
39. Id. at 112 (citing Patrick Skerrett, A Debate: Should We Edit the Human Germline?
STAT (Nov. 30, 2015), www.statncws.com/2015/11/30/gene-editing-crispr-germline).
40. 1 NAT'L INSTS. OF HEALTH, REPORT OF THE HUMAN EMBRYO RESEARCH PANEL 38
(1994) [hereinafter HUMAN EMBRYO RESEARCH PANEL].
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world." Such words can also evoke anger and stifle discussion. Yet,
the fact remains that "commentators recognize both the relative
respect to which embryonic material is entitled and [at the same
time] the value of using that material for scientific and medical
research."4 If this is true, and concomitantly if it is true that using
any one of these diverging perceptions is "not an appropriate or
useful grounding for ... analysis,"43 then chaos will envelope
human assisted reproduction. The solution lies in utilizing the
resources of a globally-connected, democratic society to balance
the respect owed to human reproductive materials and the
benefits to be achieved with each scientific development. Thus,
this Article argues that those persons or organizations with
opinions regarding human genome editing should formulate their
positions, organize, and engage with others in a public forum to
influence the progress and process of this advancement.
Human ART remains nascent in spite of startling biologic
developments.4 4 Therefore, there is little structure surrounding its
current use or future direction in the United States or elsewhere;
however, there are a few judicial pronouncements, an increasing
number of statutes and regulations, and an accelerating debate
among commentators and organizations. 45  The common
denominator among all is a plea for greater transparency in
debate and research; increased public discussion; and meaningful
"interplay between government expertise/authority and public
consultation."' In this pluralistic age, it is reasonable to conclude
41. See, e.g., JOHN H. EvANS, CONTESTED REPRODUCTION: GENETIC TECHNOLOGIES,
RELIGION, AND PUBLIC DEBATE (2010); SUSAN M. LINDEE, MOMENTS OF TRUTH IN GENETIC
MEDICINE (2005); Raphaelle Dupras-Leduc et al., Mitochondrial/Nuclear Transfer A
Literature Review of the Ethical, Legal, and Social Issues, 1 CAN. J. BIOETHICS 1 (2018);
Michael J. Sandel, Embryo Ethics-The Moral Logic of Stem-Cell Research, 351 NEW ENG. J.
MED. 207 (2004).
42. Jeter v. Mayo Clinic Arizona, 121 P.3d 1256, 1268 (Ariz. Ct. App. 2005); see also
SUZANNE HOLlAND ET AL., THE HUMAN EMBRYONIC STEM CELL DEBATE 53-54 (MIT Press
eds., 2001).
43. NAT'L ACADS. OF SCIS., ENG'G, & MED., MITOCHONDRIAL REPLACEMENT
TECHNIQUES: ETHICAL, SOCIAL, AND POLICY CONSIDERATIONS 91 (2016) [hereinafter
MITOCHONDRIAL REPLACEMENT TECHNIQUES].
44. See Rafael Bernabeu, Development of Assisted Reproduction: Past, Present, and Future
of Technologies, BIOFORUM EUR. 2, 3 (2007), https://pdfs.semanticscholar.org/d60d/c 6 7
el59add27367b4424737ca52254b9ad59.pdf.
45. See Ima E. Nsilen, Navigating the Federal Regulatory Structure ofAssisted Reproduction
Technology Clinics, AM. B. ASS'N (Sept 27, 2018), https://www.americanbar.org/groups/
health_1aw/ publications/aba-healthesource/2016-2017/november201 7/reproduction.
46. HUMAN GENOME EDITING, supra note 27, at 261.
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that the only democratic means we have to accord human
reproduction the beneficence, dignity, and respect due is to
encourage each to influence the pathway of research and practice.
The current moment seems particularly appropriate.
Science has progressed beyond IVF and now is able to permit
multiple genetic parents, inheritable germline modifications, and
enhancements of any fetus. 47 Viewing science in an optimistic
fashion, it is reasonable to expect that those with opinions
regarding these matters apprise themselves of the facts and
provide an inclusive voice in the debate that is underway. Current
procedures are nascent, and therefore, engagement can provide
guidance. Nevertheless, immediacy is warranted because
" [s] cience and technology are developing rapidly in this field. ...
[W] e should be cautious about predicting the precise form of the
technology that we might be trying to govern in 5-15 years'
time."" Fashioning a pathway today is our best method of
preparing for the future.
We have to consider not only the possibility of
technologies emerging in our own jurisdiction, but
also the possible transfer of technologies developed
elsewhere, which may import ethical problems
along with them. There is also the possibility that
moral responsibility will be diffused around the
system and will not land anywhere: international
divisibility and mobility of elements of a
technological intervention potentially lead to
'organized irresponsibility' in which moral
responsibility is distributed across jurisdictions and
never run to ground.49
This Article assesses current ART procedures, identifying
the creative function of IVF and how this procedure enables
surrogacy, genome editing, and mitochondrial replacement. The
human impact of these procedures-in such a short period of
47. See NUFFIELD COUNCIL ON BIOETHICS, supra note 14, at 11 (discussing how
germline involves "cells that give rise to sperm and eggs" and hence are heritable through
reproduction).
48. Id.at3L.
49. Id. at 54-55.
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time-is startling and, depending on each person's point of view,
precipitates optimism or alarm. What all agree upon is that
because these procedures involve human beings and potentially
impact future generations of humans, there is a need to honestly
engage interested persons and organizations in civil discourse to
address the scientific challenges.
A vibrant and interactive scientific community exists in the
United States. As such, this Article references reports from the
National Academies of Sciences, Engineering and Medicine. Also,
this Article identifies presidential councils, committees, and a host
of scientific and public policy journals. In a few instances, state
and federal courts have expressed opinions on the procedures and
public policy parameters discussed in this Article. The scientific
technology, however, moved too quickly to permit sufficient
public engagement on issues such as genome editing. Although
genome editing may be able to eradicate many diseases, it could
also enable enhancement and permanent alteration of the human
germline.o Similarly, mitochondrial replacement has an impact
on parenthood and implications for future generations.
Engagement will address those who wish to simply say "no" to the
science these procedures portend and caution those seeking
unbridled discovery to charter a transparent course.
There must be an immediacy to public engagement. The
science identified and discussed in this Article will not lie
dormant. Immediacy is further justified due in part to the
pharmaceutical industry, always alert to the economic profits
associated with containment of disease and access to fertility
enhancements. While the commercial sector petitions for approval
for the most recent scientific innovations, some are mindful of the
possibilities inherent in off-label use and the possibility of medical
tourism existent in foreign countries. Increasing insurance
coverage augments the current private pay option, providing
added incentives to create an immediate pathway to public
engagement. Interested parties concerned with these issues
cannot stand idly by.
50. See, e.g., Tetsuya Ishii, Germline Genome-Editing Research and its Socioethical
Implications, 21 TRENDS MOLECUlAR MED. 473, 479 (2015).
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II. CURRENT ART PROCEDURES
A. Beginning with IVF
ART is defined as "[a] fertility treatment or procedure that
involves laboratory handling of gametes (eggs and sperm) or
embryos [an ovum after fertilization]."" Its use has provided
"alternative methods for people to have children when it is
otherwise impossible or infeasible for them to do so naturally.""
In a significant illustration of assisted reproduction, Louise Brown
was born in 1978; this baby girl is often referenced as the first test
tube baby." Her birth through IVF was accomplished through an
assisted reproduction technique in which fertilization is
accomplished outside the body, as compared to artificial
insemination when sperm is injected into a woman and the ovum
is fertilized inside the woman's body."
Since the birth of Louise Brown, "it is estimated that more
than 5 million babies have been born as a result of IVF,"" and
"[a] lthough there are no official numbers, a conservative estimate
indicates that more than a million embryos, most of them excess
from IVF, remain in storage across the United States."" Likewise,
there are countless other embryos stored in many foreign
countries. Today, ART has come to include not only IVF, but also
gamete intrafallopian transfer (eggs and sperm are placed in the
fallopian tube and fertilization occurs in the body); zygote
intrafallopian transfer (egg is fertilized outside the body and
placed in the fallopian tube); and intracytoplasmic sperm
51. HUMAN GENOME EDITING, supra note 27, at 293; see also HUMAN EMBRYO
RESEARCH PANEL, supra note 40, at D-1 ("Embryo: in humans, the developing organism
from the time of fertilization until the end of the eighth week of gestation, when it
becomes known as a fetus.").
52. Deborah Zalesne, The Intersection of Contract Law, Reproductive Technology, and the
Market: Families in the Age ofART, 51 U. RICH. L. REv. 419, 419 (2017).
53. Dena Beth Langley, In Vitro Fertilization: Eliminating the Current State of Limbo
Between Pre-Embryonic Rights and the Fundamental Right to Procreate, 26 WAKE FOREST L. REv.
1217, 1222 n.61 (1991).
54. IVF is distinguishable from artificial insemination. Artificial insemination
involves the introduction of sperm into the uterine cavity to encourage fertilization,
whereas the IVF involves the implantation of a fertilized egg that was grown in a petri dish
back into a woman's uterus. See, e.g., Finley v. Astrue, 270 S.W.3d 849, 850 n.2 (2008).
55. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 60.
56. Id. at 105.
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injection ("ICSI") (fertilization occurs outside the woman's body
by injecting sperm into an egg). 5 1
In addition to the expanding number of human embryos
cryogenically preserved throughout the world, the number of ART
clinics, ART cycles, and infants born as a result of ART continue to
rise dramatically." The Centers for Disease Control and
Prevention ("CDC") collects and publishes data for certain
"treatments or procedures which include the handling of human
oocytes [developing egg; usually a large and immobile cell] [," or
embryos.""o In 2017, the CDC reported that in 2015 there were
499 fertility clinics operating in the United States, of which 464
provided data." These clinics reported that 231,936 fertility cycles
were started in 2015, and the number of infants born as a result
was 72,913.62 "An ART cycle is started when a woman begins taking
medication to stimulate ovaries to develop eggs" or when there is
natural egg production. 3 "If eggs are produced, then the cycle
progresses to egg retrieval, a surgical procedure in which eggs are
collected from a woman's ovaries."6 4 Once retrieved, the eggs are
then fertilized, and, if fertilization is successful, then one or more
embryos (fertilized eggs) are transferred back to the woman and
57. Casey ct al., supra note 1, at 85 (citing CTRS. FOR DISEASE CONTROL &
PREVENTION, 2013 ASSISTED REPRODUCTIVE TECHNOLOGY: FERTILITY CLINIC SUCCESS
RATES REPORT 3 (2015), https://www.cdc.gov/art/pdf/2013-report/art-2013-fertility-clini
c-report.pdf).
58. See, e.g., (TRS. FOR DISEASE CONTROL & PREVENTION, FIGURES FROM THE 2016
ASSISTED REPRODUCTIVE TECHNOLOGY NATIONAL SUMMARY REPORT 44 (2016), https://
www.cdc.gov/art/pdf/2016-national-summary-slides/ART 2016_gr-aphs-and-charts.pdf;
S. Dyer et al., International Committee for Monitoring Assisted Reproductive Technologies World
Report: Assisted Reproductive Technology 2008, 2009and 2010, 31 HUM. REPROD. 1588, 1590-
98 (2016).
59. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 62. An oocyte is
delined as a "[d]cveloping egg; usually a large and immobile cell." HUMAN GENOME
EDITING, supra note 27, at 303.
60. 42 U.S.C. § 263a-1 et seq., (2018) (mandating that clinics report data to the CDC
or face expulsion from the Society of Assisted Reproductive Technologies ("SART")).
61. CTRS. FOR DISEASE CONTROL & PREVENTION, U.S. DEP'T OF HEALTH & HUMAN
SERVS., 2015 ASSISTED REPRODUCTIVE TECHNOLOGY NATIONAL SUMMARY REPORT 7
(2017), https://www.cdc.gov/art/pdf/201.5-report/ART-2015-National-Summary-report.p
df [hereinafter 2015 CDC REPORT].
62. Id.
63. Id. at 13.
64. Id.
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the cycle may then progress to pregnancy and possibly a live
birth. 65
ART cycles have increased steadily. There were 208,604
ART cycles in 201466 and 231,936 cycles started in 2015. Both years
indicate an increase from 2013, when the CDC reported that there
were 497 clinics operational. 7 In 2013 there were 190,773 ART
cycles started, and 67,996 infants born as a result.68 Similarly, there
has been a gradual increase in persons "banking" eggs or embryos
for future use. 69 Banking occurs through cryopreservation, usually
done so a woman can avoid undergoing the retrieval process a
second time since she has "banked" sufficient eggs. 70 Banking is
popular. In fact, from 2005 through 2014, transfers of more than
one banked embryo more than tripled from nine percent to
almost twenty-nine percent.7 ' In 2014, twenty-seven percent of all
ART cycles used frozen nondonor embryos, and the percentage
rose to thirty percent in 2015.
ART is an expensive procedure, and currently, insurance
coverage is spotty.73 The cost for an ART cycle leading to a live
birth currently ranges from $66,000 to $114,000,7' depending
upon the location of the procedures. Moreover, a live birth may
include many ART cycles.7 ' There are those who argue that
competition among clinics and the increased possibility of
insurance coverage may contribute to a reduction in price.76
Decreasing cost will also increase the number of persons able to
65. Id.
66. CTRS. FOR DISEASE CONTROL & PREVENTION, U.S. DEP'T OF HEALTH & HUMAN
SERVS., 2014 ASSISTED REPRODUCrIVE TECHNOLOGY NATIONAL SUMMARY REPORT 3
(2016), https://www.cdc.gov/art/pdf/2014-report/ART-2014-National-Summary-report.p
df [hereinafter 2014 CDC REPORT].
67. 2015 CDC REPORT, supra note 61, at 7; CTRS. FOR DISEASE CONTROL &
PREVENTION, U.S. DEP'T OF HEALTH & HUMAN SERVS., 2013 ASSISTED REPRODUCTIVE
TECHNOLOGY NATIONAL SUMMARY REPORT 7 (2015), ftp://ftp.cdc.gov/pub/Publication
s/art/ART-2013-Clinic-Report-Full.pdf [hereinafter 2013 CDC REPORT].
68. 2013 CDC REPORT, supra note 67, at 7.
69. 2014 CDC REPORT, supra note 66, at 8; 2015 CDC REPORT, supra note 61, at 8.
70. 2015 CDC REPORT, supra note 61, at 63.
71. 2014 CDC REPORT, supra note 66, at 55.
72. 2014 CDC REPORT, supra note 66, at 8; 2015 CDC REPORT, supra note 61, at 8.
73. See Katie Falloon & Philip M. Rosoff, Who Pays? Mandate Insurance Coverage for
Assisted Reproductive Technology, 16 AM. MED. ASS'NJ. ETHICs 63, 63 (2014).
74. Id.
75. See id.
76. See Zalesne, supra note 52, at 445; see also Casey et al., supra note 1, at 113-15.
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utilize the procedures, and insurance may provide greater
accountability of services offered. Presently fifteen states have
enacted legislation requiring private insurance to cover all or
some of the cost of infertility treatments. 7 7 Interestingly, the states
mandating coverage illustrate the acceptance of ART among all
geographical areas of the United States. The states include:
Arkansas, California, Connecticut, Hawaii, Illinois, Louisiana,
Maryland, Massachusetts, Montana, New Jersey, New York, Ohio,
Rhode Island, Texas, and West Virginia.7 ' Even though the laws
vary among these states,7 1 it is the acceptance of the procedures
which suggests ART will continue to expand among all parts of the
population. This acceptance prompts the social acceptance of
another form of IVF: surrogacy.
B. After IXF Surrogacy
Surrogacy has been practiced since biblical times,so
through a method which involve what we now term genetic
surrogacy. A genetic surrogate is defined as "a woman who is not
an intended parent and who agrees to become pregnant through
assisted reproduction using her own gamete [eggs], under a
genetic surrogacy agreement.""' Compare this woman to a
gestational surrogate, defined as "a woman who is not an intended
parent and who agrees to become pregnant through assisted
reproduction using gametes that are not her own, under a
gestational surrogacy agreement. Obviously, the distinction
involves the fact that a genetic surrogate uses her own ovum,
thereby sharing a genetic link with the resulting infant. Very few
states permit genetic surrogacy, and those that do mandate a
comprehensive statutory scheme, such as allowing the genetic
surrogate to withdraw consent to surrender the baby within a
77. State Laws Related to Insurance Coverage for Infertility Treatment, NAT'L. CONF. ST.
LEGISLATURES (Apr. 27, 2018), http://www.ncsI.org/rcsearch/health/insuance-covcrage-
for-infe rtility-laws.aspx.
78. Id.
79. See, e.g., ARK. CODE ANN. § 23-85-137, 23-86-118 (2014); CAL. HFALTH & SAFETY
CODE § 1374.55 (Deering 2010); CAL. INS. CODE § 10119.6 (Deering 2018); NJ. STAT.
ANN. §§ 17:48A-7w, 17:48E-35.22, 17B:27-46.1x (West 2018).
80. See Genesis 16:1-16.
81. UNIF. PARENTAGE Acr § 801(1) (NAT'L CONFERENCE OF COMM'RS ON UNIF.
STATE LAWS 2017).
82. Id. § 801(2).
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specified time after birth." In the United States today, of the states
that permit surrogacy, most permit only gestational surrogacy
agreements. 8 4
In spite of initial judicial and legislative rejections of
surrogacy agreements8 5 the practice of surrogacy has "become
increasingly socially accepted, and even welcomed."8  One
commentator writes that "a look at the hundreds of legal and
ethical research studies that have been published in recent
decades demonstrates the recent shift and accelerated social and
legal acceptance of the surrogacy practice."87 Illustrative of this
trend towards acceptance is the 2017 revision to the Uniform
Parentage Act.8 The National Conference of Commissioners on
Uniform State Laws, which drafted the revised Uniform Parentage
Act, acknowledged that "much has changed in this rapidly
developing area of law and practice in the last 15 years."89 In
addition, commentators note that, "[i]iberalization of surrogacy
and a wider acceptance of the practice are linked to the expansion
of rights for gay couples-the human rights issues that propelled
legalization of gay marriage also drove reform in the area of
surrogacy.""o Since adoption and gestational surrogacy are two
options by which same-sex couples may become parents, it follows
that surrogacy became more acceptable as marriage equality
became more acceptable." Concomitantly, IVF has permitted the
shift from genetic surrogacy to greater acceptance and utilization
83. See, e.g., D.C. CODE § 16-411(4) (2018); FLA. STAT. ANN. § 63.213 (2018); VA.
CODE ANN. § 20-161(B) (2016); UNIF. PARENTAGE AcT § 814 CMT.
84. See, e.g., DEL. CODE ANN. tit. 13, §§ 8-801-809 (2016); 750 ILL. COMP. STAT. ANN.
47/1-75 (West 2018); ME. REV. STAT. ANN. it 19-A, §§ 1931-1938 (2017); NEV. REV. STAT.
ANN. §§ 126.500-810 (LexisNexis 2016); N.H. REV. STAT. ANN. §§ 168-B:1-22 (LexisNexis
2017); UNIF. PARENTAGE ACT § 814 cmt.
85. See, e.g., In re Baby M., 525 A.2d 1128 (N.J. 1987) (rejecting a genetic surrogacy
agreement as violative of public policy); see also IND. CODE §§ 31-20-1-1-3 (2017) (banning
all types of surrogacy agreements).
86. Yehenzkel Margalit, In Defense of Surrogacy Agreements: A Modern Contract Law
Perspective, 20 WM. & MARYJ. WOMEN & L. 423 (2014); see, e.g., P.M. v. T.B., 907 N.W.2d
522, 530-31 (Iowa 2018) (holding that a gestational surrogacy contract was enforceable
and did not violate public policy); see also Kamel, supra note 1, at 96-98.
87. Margalit, supra note 86, at 437.
88. UNIF. PARENTAGE ACT art. 8.
89. Id.
90. Zalesne, supra note 52, at 428.
91. Id.
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of gestational surrogacy,9 even while recognizing increasing
public acceptance of genetic surrogacy."
Surrogacy still follows a patchwork format among the
states." There is no federal legislation; thus, state courts are
leading the way in upholding surrogacy agreements, often without
the assistance of state statutes. "California is generally considered
to be the most favorable for prospective parents." The California
Supreme Court stated that it is "not the role of the judiciary to
inhibit the use of reproductive technology when the legislature
has not seen fit do so; any such effort would raise serious questions
in light of the fundamental nature of the rights of procreation and
privacy."" California mirrors other more modern state courts that
tend to be more permissive, even in jurisdictions otherwise not
considered liberal. On the other hand, it appears that " [t]he least
permissive jurisdictions tend to be ones without binding case law
or ambiguous statutory language, but nonetheless have trial courts
skewing in favor of enforcing surrogacy contracts." Overall, the
trend is towards enforcing surrogacy agreements," which has
implications for genome editing, including mitochondrial
replacement.
The increasingly permissive stance of state courts towards
surrogacy is demonstrated by a decision from the Iowa Supreme
Court," which discusses the utilization and acceptance of ART
among the general population. The case involved whether to
enforce a gestational surrogacy agreement, providing a question
of first impression under Iowa law." Plaintiffs were a married
couple, unable to conceive their own child, and signed an
92. Id. at 429-30.
93. See, e.g., In rePaternity of F.T.R., 833 N.W.2d 634 (Wis. 2013) (holding that there
was no state public policy objection to enforcing a genetic surrogacy agreement as long as
the mother's parental rights were protected).
94. Surrogacy Laws, SURROGACY EXPERIENCE, https://www.thesurrogacycxperience.
com/u-s-surrogacy-law-by-state.html (last visited Mar. 22, 2019).
95. Casey et al., supra note 1, at 100 (citing Darra L. Hofman, Mama's Baby, Daddy's
Maybe: A State-by-State Survey of Surrogacy Laws and Their Disparate Gender Impact, 35 WM.
MITCHELL L. REv. 449, 460 (2009)).
96. Id. at 100 (quoting Johnson v. Calvert, 851 P.2d 776, 787 (Cal. 1993)).
97. Casey ct al., supra note 1, at 103.
98. Id.
99. P.M. v. T.B., 907 N.W.2d 522, 522 (Iowa 2018); see alsoJ.F. v. D.B., 879 N.E.2d
740, 740 (Ohio 2007) (enforcing the agreement because there was no public policy
prohibiting this).
100. P.M., 907 N.W.2d at 524.
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agreement with defendants, the surrogate and her husband; in
exchange for "$13,000 and medical expenses, [the defendants]
agreed to have the surrogate mother impregnated with embryos
fertilized with the plaintiff-father's sperm and the ova (eggs) of an
anonymous donor."'O' After the surrogate became pregnant with
twins, she demanded additional monetary payments from the
plaintiffs; after the plaintiffs refused, defendants breached the
surrogacy agreement.1 0 2 Eventually, the babies were born
prematurely and one infant died, but the defendants continued to
refuse to surrender the surviving infant to the plaintiffs.'0 o
Whereupon the intended parents/plaintiffs sued to enforce the
agreement and to gain custody of the surviving child.'0 4 The state
district court ordered a genetic test, ruled that the agreement was
enforceable, terminated the presumptive parental rights of the
surrogate mother and her husband, and established paternity with
the biological father, awarding him permanent legal and physical
custody of the baby.'05 The defendants appealed. 0 '
The Iowa Supreme Court affirmed the district court's
holding that there were neither statutory nor public policy
prohibitions and that "this child would not have been born,
without [the plaintiffs'] reliance on the surrogate's contractual
commitment."' Illustrative of the increasing acceptance of ART,
reproductive freedom, and genetic parenthood, the court noted
that any "contrary holding invalidating surrogacy contracts would
deprive infertile couples of the opportunity to raise their own
biological children and would limit the personal autonomy of
women willing to serve as surrogates to carry and deliver a baby to
be raised by other loving parents."1O Furthermore, the court held
that surrogacy cannot be contrary to public policy because
" [b] anning gestational surrogacy contracts would deprive infertile
couples of perhaps the only way to raise their own biological
101. Id. at 525.
102. Id.
103. Id. at 528.
104. Id.
105. Id.
106. Id. at 525.
107. Id.; see also IOWA CODE § 710.11 (2017) (exempting genetic surrogacy
arrangements from criminal penalties associated with selling babies but silent as to
gestational arrangements).
108. P.M., 907 N.W.2d at 525.
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children and would limit the contractual rights of willing
surrogates." 09
While the facts of the Iowa decision are pertinent to this
specific opinion, the decision may have broader applicability. The
case also identifies arguments made in other ART procedures,
such as genetic editing and mitochondrial replacements. Asserted
entitlements to these procedures also are based in claims of
individual personal autonomy, reproductive freedom, the value of
a genetic relationship, and the right to freedom of contract."o The
surrogate had no genetic relationship to the baby; this was a
gestational surrogacy, not a genetic surrogacy.11 ' The court wrote:
"We agree with other courts that recognize the difference between
surrogacy arrangements and giving up one's own genetic child for
adoption. "112 Such a distinction exists between genetic and
gestational surrogacy, a distinction mandated in some other
states."' In addition, this was a surrogacy agreement executed by
competent consenting adults." 4 Relying on precedent from other
state courts, the Iowa high court ruled that freedom of contract
should be honored, and that absent fraud, duress, or
unconscionability, surrogacy agreements do not violate public
policy."' Indeed, the court "conclud[ed] that gestational
surrogacy agreements promote families by enabling infertile
couples to raise their own children and help bring new life into
this world through willing surrogate mothers."" 6
The 2018 Iowa decision shows a change in public attitude
not just towards surrogacy but also towards IVF in general. This
109. Id. at 533-34.
110. Id. at 525.
111. Id.
112. Id. at 536.
113. Courtney G. Joslin, Nurturing Parenthood Through the UPA (2017), 127 YALE L.J.F.
589, 610 (2018) ("[T]he political reality [is] that state legislators have been more
reluctant to enact legislation expressly permitting [genetic] surrog-acy.").
114. P.M., 907 N.W.2d at 533.
115. Id. at 540, 544 (noting the agreement the surrogate signed stated: "[S]he has
carefully read and understood every word in this agreement and its legal effect, and each
party is signing this agreement freely and voluntarily and that neither party has any reason
to believe that the other party of parties did not understand fully the terms and effects of
this agreement, or that the other party did not freely and voluntarily execute this
agreement.").
116. Id. at 539; see also In re Parentage of F.T.R., 833 N.W.2d 634, 649-50 (Wis. 2013)
(holding that a genetic surrogacy agreement should be upheld in part, because it
safeguarded family expectations).
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change in perspective-minimal in regard to gestational
surrogacy-suggests that first courts, and then legislatures, accept
that "technology does not threaten the institution of
motherhood.""' It is a fact of life that scientific and technological
advances continue to progress. Scientific developments such as
surrogacy may now include: (1) intrauterine or intracervical
insemination; (2) donation of gametes; (3) donation of embryos;
(4) IVF and transfer of embryos; and (5) intracytoplasmic sperm
injection."' Traditionally, "marital love making and baby making
have gone hand in hand, [whereas] surrogacy and gamete
donation involve a medical intervention that necessarily separates
procreation from love and sexual intercourse."" 9 Can it be that
what constitutes parenthood evolves with society? There are those
who argue that today's public perception shift is based on an
understanding that "parenthood [is] a moral relationship rather
than a biological one, and the best interest of the child [is] being
determined by social conditions and functional parenthood, not
biological relations." 1 20
Undoubtedly, greater societal acceptance of surrogacy
agreements arose in part because of greater social access to
technology generally. Media, smart phone interconnectivity, and
the vast array of data portals have made technology accessible and
hence friendlier to millions."' This immersion in technology has
an impact on culture. Also, there is greater acceptance of same-sex
couples,12 2 who are unable to access parenthood through sexual
intercourse. Marriage equality occurred after the Supreme Court
declared that both marriage and marriage recognition were
mandated by force of the United States Constitution throughout
117. Zalesne, supra note 52, at 432.
118. UNIF. PARENTAGE ACT § 102(4).
119. Zalesne, supra note 52, at 432, 433 ("Reproduction is no longer sacred when a
woman carries a child she has no desire to raise, when she gives her eggs to a fertility
clinic so she can pay her student loans, or when she harvests her eggs for the future with
acknowledgement that she does not want to have children yet.").
120. Id. at 439.
121. Scott Jones, How Technology Has Increased Our Access to Information and Answers-
Not All of Them Right, REAL-TIME DAILY (Sept. 16, 2013), https://www.mediapo
stcom/publications/article/209205/how-technology-has-increased-our-access-toinforma.
html.
122. Michael S. Wald, Same Sex Couple Marriage: A Family Policy Perspective, 9 VA.J. Soc.
POLY. & L. 291, 291-92 (2002).
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all states.' It follows that marriage equality led to increased rates
of surrogacy or IVF among same-sex couples who were finally able
to access the constellation of benefits attendant upon marriage. 14
An illustration of the modern acceptance of same-sex
couples can be found in the newly revised Uniform Parentage Act
("UPA"). "The UPA (2017) addresses [any] potential
constitutional infirmity by making the marital presumption
expressly apply equally to both male and female spouses of the
woman who gave birth."'12  With this modification to the UPA,
"many more of these married same-sex parents will have legally
recognized relationships with their children, and these families
will have greater certainty and security regarding their familial
relationships as they travel about the country. "126
Wherever surrogacy is not accepted in the United States,
persons or couples may use the services of another state or
execute a surrogacy contract with a woman in a foreign country.' 7
Foreign surrogacy may be termed transnational surrogacy and
recognizes the willingness of parties to engage in medical
tourism.' Thailand and Mexico, among other countries, permit
the enforcement of surrogacy contracts between foreigners and
local women willing to carry a child to term and subsequently
surrender the child after birth.'12 Some countries, such as India,
banned foreign surrogacy contracts, a development that signaled
greater scrutiny of contractual clauses that possibly involve
economic coercion, inadequate consent, sex-based selection of
embryos, and improper treatment of the young women who serve
123. See Obergefell v. Hodges, 135 S. Ct. 2584, 2604-05 (2015); see also O'Brien, supra
note 15, at 420-22.
124. See Pavan v. Smith, 137 S. Ct. 2075, 2076-77 (2017) (holding that same-sex
couples must be granted identical status with opposite-sex couples).
125. Joslin, supra note 113, at 609.
126. Id. at 612.
127. Adeline A. Allen, Surrogacy and Limitations to Freedom of Contract: Toward Being
More Fully Human, 41 HARV.J.L. & PUB. PoL'Y, 753, 757-58 (2018).
128. April L. Cherry, The Rise of the Reproductive Brothel in the Global Economy: Some
Thoughts on Reproductive Tourism, Autonomy, and justice, 17 U. PA.J.L. & Soc. CHANGE 257,
259-60 (2014).
129. See Allen, supra note 127, at 808 (arguing that foreign surrogacy contracts should
be invalid as contrary to public policy). But see Sharmila Rudrappa, Why is India's Ban on
Commercial Surrogacy Bad for Women?, 43 N.C.J. INT'L L. 70, 91-92 (2018) (arguing that
surrogacy is a valid form of employment for women and should be permitted).
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as the surrogates.'s Obviously, debate over the enforcement of
foreign surrogacy contracts ranges from issues of financial
exploitation, adequacy of consent, reproductive freedom, and
general public policy.'"' Although the debate today centers on the
validity of the surrogacy agreement, tomorrow international ART
will permit more options than whether to enforce a surrogacy
contract. Efforts in the United States to address genome editing or
mitochondrial replacement must address medical tourism as it
relates to foreign availability. People seek out surrogates today, but
tomorrow's "add-on" services may include gender selection,
"designer babies," or the parental rights of a child with a genetic
connection to multiple genetic donors.'13 Transnational surrogacy
is the subject of current discussion, but the future will involve
more expansive medical procedures and challenges.3
C. After IVF: Genome Editing
In 1953, scientists first achieved the ability to define the
structure of DNA. 34 Fewer than fifty years later, in 1999, the
human genome was first fully sequenced. 3 - "The human genome
is contained in 23 pairs of chromosomes, 22 autosomes and 1 pair
of sex chromosomes, in a sequence of paired chemical bases that
are held together in the long molecules of ... [DNA] that are
present in almost all the cells of the body."' 3 Subsequently, within
130. See, e.g., Sarah Mortazavi, It Takes a Village to Make a Child: Creating Guidelines for
International Surrogacy, 100 GEO. L.J. 2249, 2282-83 (2012); Barbara Stark, Transnational
Surrogacy and International Human Rights Law, 18 ILSAJ. INT'L & COMP. L. 369, 370 (2012);
Richard Storrow, "The Phantom Children of the Republic": International Surrogacy and the New
Illegitimacy, 20 AM. U.J. GENDER SOC. POL'Y & L. 561, 567 (2012).
131. Cherry, supra note 128, at 274-77.
132. See Margalit, supra note 86, at 130.
133. See, e.g., Molina B. Dayal et al., Preimplantation Genetic Diagnosis, EMEDICINE (Aug.
29, 2018), https://emedicine.medscape.com/article/273415-overview#section-bibliogra
phy; see also Aziza Ahmed, Race and Assisted Reproduction: Implications for Population Health,
86 FORDHAM L. REV. 2801, 2807-08 (2018); Tara R. Melillo, Note, Gene Editing and the Rise
of Designer Babies, 50 VAND.J. TRANSNAT'L L. 757, 765-67 (2017).
134. Watson and Crick Discover Chemical Structure of DNA, HISTORY (Feb. 28, 2019),
https://www.history.com/this-day-in-history/watson-and-crick-discover-chemical-strucure-
of-dna.
135. Scientists Complete First Chapter of Book of Life with Decoding of First Human
Chromosome, NAT'L HUM. GENOME RES. INST., https://www.genome.gov/10002104/1999-
release-first-human-chromosome-sequenced (last updated July 28, 2006).
136. NUFFIELD COUNCIL ON BIOETHICS, supra note 14, at 7.
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ten years scientists made specific small changes to the genome." 7
By the mid-2000s, genome editing became possible, followed by
methods based on protein recognition of specific DNA
sequences.' 3 8 The original editing technology was expensive and
difficult to work with in laboratories, 139 but continuing scientific
advances made it possible to perform genome editing less
expensively and on a broader scale.' Undoubtedly, the future will
bring even more efficient methods.
Genome editing involves "making precise additions,
deletions, and alterations to the genome-an organism's complete
set of genetic materials." 4 ' The possibilities resulting from this
process are nothing less than extraordinary. The National
Academies of Sciences, Engineering and Medicine summarized
the potential in its 2017 report:
Genome editing offers great potential to advance
both fundamental science and therapeutic
applications. Basic laboratory research applying
genome-editing methods to human cells, tissues,
germline cells, and embryos holds promise for
improving understanding of normal human
biology, including furthering knowledge of human
fertility, reproduction, and development, as well as
providing deeper understanding of disease and
establishing new approaches to treatment.1 2
Genome editing involves changing the genome sequence
"by adding, replacing, or removing DNA base pairs." 143 Such
editing would permit among, other applications, "restoring
normal function in diseased organs by editing somatic cells to
prevent[] genetic diseases in future children and their
137. Jay W. Cormier & Ricardo Carvajal, Ready or Not, CRISPR and Gene Editing Have
Arrived and Are Here to Stay, UPDATE (July/Aug. 2016), at 4-5, http://newsite.hpm.c
om/pdf/CRISPR%20AND%20GENE%20EDITING%20JYC%20RC.PDF.
138. See id.
139. Id. at 4.
140. See id. at 4-5 ("[D]cpending on the application, the distinction between gene
editing and genetic engineering may really be a distinction without a difference.").
141. HUMAN GENOME EDITING, supra note 27, at 1.
142. Id. at 181.
143. Id. at 1 n.2.
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descendants by editing the human germline."'" In application,
"existing and forthcoming genomic sequencing tools have the
potential to allow for revolutionary science, including direct
sequencing of RNA or proteins, real-time genomic pathogen
monitoring or precision medicine based on personal genome
sequencing. "145
In August 2017, a team from the Oregon Health & Science
University corrected a genetic defect in a human zygote that led to
the development of viable embryos."' "This research shows that
correcting a gene mutation in viable human embryos using
genome editing methods is feasible." 4 7 Focusing just on the
beneficial aspects of genome editing, the possibilities seems
bountiful and endless. Indeed, "[iun 2017 alone, CRISPR
technologies enabled researchers to remove HIV from living
animals, edit out Huntington's disease in mice, slow the growth of
cancerous cells, and open the door to the eradication of mosquito-
borne diseases.""' Overall, "[t]he discovery of CRISPR, and its
ability to precisely locate and delete genetic mutations, brings the
scientific community closer than ever before to the possible
eradication of a number of debilitating monogenetic diseases."I49
Among these diseases are cystic fibrosis, sickle-cell disease, and
Duchenne muscular dystrophy, all monogenic diseases that result
from a single mutation along the human genome.15 0
However, because editing a human genome could have
unforeseen consequences for future generations, there is concern
despite great promise. For example, international concerns were
uniformly expressed at the Second International Summit on
Human Genome Editing in November 2018, when it was
announced that a rogue scientist in China edited genes in twin
144. Id. at 1.
145. Kevan M.A. Gartland et al., Advances in Biotechnology: Genomics and Genome
Editing, I EUROBIOTECHJ. 2, 4 (2017).
146. Giovanni Rubeis & Florian Steger, Risks and Benefits ofHuman Germline Genome
Editing: An Ethical Analysis, 10 ASIAN BIOETHIcS REv. 133, 135 (2018).
147. Id.
148. Tracey Tomlinson, A CR1SPR Future for Gene-Editing Regulation: A Proposal for an
Updated Biotechnology Regulatory System in an Era of Human Genomic Editing, 87 FORDHAM L.
REv. 437, 441 (2018).
149. Id. at 447.
150. Id.
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girls who were subsequently born.15' Likewise, concerns were
raised when a boy was born in Mexico after a mitochondrial
replacement. 1 52 There were also many concerns raised over a
slippery slope towards designer babies, accentuated class
distinctions, and a resurgence of human eugenics.1 53
i. The Science
Currently there are four methods used to edit any gene.
These include: Zinc Finger Nucleases, Transcription Activator-
Like Effector Nucleases, Clustered Regularly Interspaced Short
Palindromic Repeats ("CRISPR/Cas9") Nuclease, and the use of
Cpfl as an alternative to Cas 9 nuclease.'" CRISPR/Cas9 is used
most often by scientists, as it "can be engineered more easily and
cheaply than these other methods to generate intended edits in
the genome."1 5 5 While the scientific technology and uses of
genome editing is beyond the scope of this Article, it is pertinent
to know that "CRISPR technology is a molecular tool that was
created by making adjustments to a bacterial immune system."1 56 It
can be harnessed because:
The bacterial genome contains a number of
repeating DNA sequences that are used by the
bacteria to determine whether a virus is infecting
the cell, and, if so, to use a specific enzyme that
targets the viral DNA to cut the DNA into pieces....
[The] repeating pieces of DNA in the bacterial
genome [are] to help the bacteria identify the same
virus again the next time the virus attempts to infect
the bacteria.... [The CRISPR/Cas9 system is
151. Org. Comm. of the Second Int'l Summit, On Human Genome Editing II, NAT'L
ACADS. Sci., ENGINEERING, & MED. (Nov. 29, 2018), http://www8.nationalacademies
.org/onpine ws/newsitem.aspx?RecordlD=1 1282018b.
152. See Sara Reardon, 'Three-Parent Baby' Claim Raises Hopes-And Ethical Concerns,
NATURE 17 (Sept. 28, 2016), https://www.nature.com/news/three-parent-baby-claim-rais
es-hopes-and-ethical-concerns-1.20698.
153. See Frank K. Salter, Eugenics, Ready or Not, QUADRANT (May 11, 2015), https://q
uadrant.org.au/magazine/2015/05/eugenics-ready.
154. Gartland et al., supra note 145, at 5; see also HUMAN GENOME EDITING, supra note
27, at 2.
155. HUMAN GENOME EDITING, supra note 27, at 2; see Cormier & Carvajal, supra note
137, at 9 (" [Y]ou can order your own CRISPR/Cas kit for as little as $130.").
156. Cormier & Carvajal, supra note 137, at 7.
[Vol. 9:3444
2019] GENOME EDITING AND MITOCHONDRIAL REPLACEMENT 445
fundamentally the same as traditional rDNA
technologies because it] uses engineered nucleotide
sequences to selectively target sequences in an
organism's genome to make specific intentional
changes, whether insertions, deletions, or changes
in one base pair or an entire gene.'15
Technology will continue to evolve.s58  For example,
another description of developing CRISPR/Cas 9 technology
describes the process as follows:
[Using] two key molecules that introduce a change
or mutation into the DNA: first, an enzyme called
Cas9 acts as a molecular scissors by cutting the two
strands of DNA at a specific location in the genome
so that pieces of DNA can then be added or
removed and, secondly, a piece of RNA called guide
RNA or gRNA. This consists of a small piece of pre-
designed RNA sequence (about twenty bases long)
located within a longer RNA scaffold. The scaffold
part binds to DNA and the pre-designed sequence
guides the Cas9 enzyme to the right part of the
genome so that it cuts at the intended point in the
genome. In theory, the guide RNA will bind only to
the target sequence and not to other regions of the
DNA. Once the Cas9 enzyme makes a cut across
both strands of the DNA, the cell recognizes that its
DNA is damaged and tries to repair it. The
technology can be used to introduce changes to one
or more genes in a cell.159
157. Id. at 5-6.
158. See, e.g., HUMAN GENOME EDITING, supra note 27, at 227-31. "[O]ther strategies
will undoubtedly be forthcoming and should further improve the process, based on
knowledge of CRISPR/Cas9 structure." Id. at 228.
159. Yvonne Cripps, The Global Person: Pig-Human Embryos, Personhood, and Precision
Medicine, 25 IND. J. GLOBAL LEGAL STUD. 701, 705-06 (2018) (citing Alex Reis et al.,
CRISPR/Cas9 & Targeted Genome Editing: New Era in Molecular Biology, NEW ENG. BIO1ABS
(2014), https://www.neb.com/tools-and-resources/feaure-aricles/crispr-cas9-and-targete
d-genome-editing-a-new-era-in-molecular-biology); see also HUMAN GENOME EDITING, supra
note 27, at 217-18.
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While gene editing as applied to animals, specifically pigs,
has been studied by Chinese and Korean scientists,o60  an
increasing range of genome-edited agricultural products have
been considered as not requiring United States Department of
Agriculture oversight and are hence able to proceed to market
without regulation.' Indeed, scientists have already used CRISPR
gene editing to create better crops and produce a larger amount
of food. 1 2
Currently, at least five genome-edited crop plants have
been produced, including wheat, mildew-resistant white
mushrooms, and herbicide-tolerant canola.163 More are on the
way. The "genetic manipulation of animals has been the basis for
much of the research aimed at understanding embryonic
development and human diseases."164 The Washington Post
reports that by 2019 "the first foods from plants or animals that
had their DNA 'edited' are expected to begin selling."' 6 5
Specifically, scientists:
[A]re pursuing more ambitious changes: Wheat
with triple the usual fiber, or that's low in gluten.
Mushrooms that don't get brown, and better
producing tomatoes. Drought-tolerant corn, and
rice that no longer absorbs soil pollution as it grows.
160. See Karen Weintraub, Gene-Editing Success Brings Pig-to-Human Transplants Closer to
Reality, SC. AM. (Aug. 10, 2017), http://www.scientificamerican.com/article/gene-
editing-success-brings-pig-to-human-transplants-closer-to-reality; see also Cormier &
Carvajal, supra note 137, at 6 (detailing that the goal is to produce pigs with multiple
genetic edits with an aim to produce organs for xenotransplantation into humans); David
Cryanoski, Super-Muscly Pigs Created by Small Genetic Tweak, 523 NATURE 13, 13-14 (2015).
161. Gartland et al., supra note 145, at 7; see also U.S. ENVTL. PROT. AGENCY, U.S.
FOOD & DRUG ADMIN. & U.S. DEP'T AGRIC., MODERNIZING THE REGULATORY SYSTEM FOR
BIOTECHNOLOGY PRODUCTS: FINAL VERSION OF THE 2017 UPDATE TO THE COORDINATED
FRAMEWORK FOR THE REGULATION OF BIOTECHNOLOGY (2017), https://obamawhi
tehouse.archives.gov/sites/default/files/microsites/ostp/20 1 7coordinated-framework
update.pdf.
162. See Dom Galcon, Geneticists Have Used CRJSPR Gene Editing to Create Crops That
Grow More Food, FUTURISM (Sept. 14, 2017), https://futurism.com/geneticists-have-used-
crispr-gene-editing-to-create-crops-that-grow-more-food.
163. Gartland et al., supra note 145, at 7. For a summary of FDA and federal
regulatory policy for ensuring the safety of biotechnology products, see Cormier &
Carvajal, supra note 137, at 7-9.
164. HUMAN GENOME EDITING, supra note 27, at 231.
165. Lauran Necrgaard, From Salad Dressing to Granola Bars, Gene-Edited Foods Are
Coming Soon, WASH. POST, Nov. 27, 2018, at E6.
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Dairy cows that don't need to undergo painful
dehorning and pigs immune to a dangerous virus
that can sweep through herds. 6 6
The Department of Agriculture reports that new rules are
not needed for plants, but the FDA proposed tighter restrictions
on gene-edited animals; the agency reported it will provide further
guidance in 2019.167
It is one thing to edit animals and agricultural products,
however, genome editing is most controversial when the new
technology involves human subjects,' 8 especially when the edits
may potentially affect the germline. Nonetheless, in spite of
ethical, moral, and legal concerns voiced by domestic and
transnational commissions, the pace of human genome editing is
escalating rapidly.'69 It is this rapid development that prompts a
sense of immediacy when discussing genome editing and
applications, such as mitochondrial replacement. "Genome
projects are taking place on increasingly large scales, such as the
Personal Genome Project, in collaboration with Veritas Genetics,
and in the United Kingdom, through the 100,000 Genomes
Project, led by National Health Service England;" furthermore,
the project in the United Kingdom "aims to sequence 100,000
whole patient genomes from sufferers of 100 rare diseases and
seven different types of cancer, within three years."o70 By mid-2016,
there were more than 2,400 gene-transfer trials, most located in
the Americas and Europe, but nonetheless occurring on every
populated continent, with the number growing each year."' At the
Second International Summit on Human Genome Editing in
2018, scientists simultaneously denounced gene-edited babies and
rejected any moratorium on defined clinical trials.7 2
166. Id.
167. Id.
168. Skerrett, supra note 39.
169. Gartland et al., supra note 145, at 8.
170. Id. at 5 ("This project involves 13 'Genomic Medical Centres' and 85 NHS
Trusts, comprising 1,500 staff and is linked to 2,500 researchers worldwide.").
171. HUMAN GENOME EDITING, supra note 27, at 264.
172. See Rob Stein, Science Summit Denounces Gene-Edited Babies Claim, But Rejects
Moratorium, NPR (Nov. 29, 2018, 2:06 AM), https://www.npr.org/sections/health-sho
ts/2018/11/29/671657301.
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Because of the scope of the existing and planned projects
and the promise of future innovations, several commercial
partners have become increasingly involved. Among these are
Illumina for bioinformatics analysis including sequencing, data
storage, and interpretation.11 "Twelve commercial pharma,
biotech and diagnostics partners have come together through the
Genomics Expert Network for Enterprises (GENE) Consortium to
be able to use 5,000 whole genome sequences and participant
health information on an annual subscription basis, costing in
excess of £600,000 per company."174 Not surprisingly, there is
increasing interest by commercial enterprise, because " [g] enome
editing holds great promise for ... preventing, ameliorating, or
eliminating many human diseases and conditions."`75 Indeed, the
promise of genome editing includes "possibilities rang[ing] from
restoring normal function in diseased organs by editing somatic
cells to preventing genetic diseases in future children and their
descendants by editing the human germline."'76 With this promise
comes "substantial public support for the use of gene therapy
(and by extension, gene therapy that uses genome editing)."
Undoubtedly, the genome commercial enterprise "will lead to
significantjob creation opportunities, through drug development,
new diagnostic tests, treatments, medical devices and ancillary
services, alongside direct patient benefits.", 7 1 While the human
benefits would be extraordinary, the economic benefits derived
from these services would be too.
ii. Public Discussion
Because the technology is currently available, inexpensive,
and the benefits both tempting and potentially lucrative, human
genome editing is a reality. Concomitantly, issues arise pertaining
to the ethical, moral, and policy considerations involved in any
procedure that affects living persons and potentially future
generations of humans.
173. Gartland et al., supra note 145, at 5.
174. Id.
175. HUMAN GENOME EDITING, supra note 27, at 33.
176. Id. at 1.
177. Id. at 109.
178. Gartland et al., supra note 145, at 5.
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The ethical issues regarding the appropriate (and
inappropriate) use of CRISPR/Cas technology
require such international coordination that the
National Academy of Sciences, together with
Chinese Academy of Sciences and the Royal Society
of the United Kingdom, formed a Human Gene-
Editing Initiative and held an International Summit
on Gene Editing in Washington D.C. in December
2015.7
This was the first such summit; by the time of the second
summit in 2018, twin girls with edited genomes had been born.so
In 2017, a report was published by the National Academies of
Sciences recognizing that " [g] enome editing holds great promise
for preventing, ameliorating, or eliminating many human diseases
and conditions.""8 However, " [a]long with this promise comes the
need for ethically responsible research and clinical use."1 8 2 In a
concession to the complexity of providing oversight, the Report
recommends seven principles to guide governance of human
genome editing.' These principles are: (1) promoting well-being;
(2) transparency; (3) due care; (4) responsible science; (5)
respect for persons; (6) fairness; and (7) transnational
cooperation.' 8 4 These principles are not isolated-they illustrate a
theme expressed throughout the Report, "that human genome
editing has raised, and will continue to raise, ethical, regulatory,
and sociopolitical questions that go well beyond discussions of
technical risks and benefits identified by biologists or even
philosophical and sociopolitical concerns raised by social scientists
and ethicists." 8 5 In matters so important to human life, public
discussion and input is an essential parallel to scientific
advancements. The Obama administration termed public
discussion as "responsible development," which is defined as
179. Cormier & Carvajal, supra note 137, at 7.
180. NAT'L AcADS. OF Scis., ENG'G, & MED., SECOND INTERNATIONAL SUMMIT ON
HUMAN GENOME EDITING: CONTINUING THE GLOBAL DISCUSSION: PROCEEDINGS OF A
wORKSHOP-IN BRIEF 2 (Jan. 2019), https://www.nap.edu/read/25343/chapter/1.
181. HUMAN GENOME EDITING, supra note 27, at 182.
182. Id.
183. Id. at 182-84.
184. Id.
185. Id. at 164-65 (internal citations omitted).
WAKE FOREST JOURNAL OF LAW & POLICY
communication and consultation."" The rapidity of scientific
development, the plurality of opinions available, and the human
importance necessitates public discussion. Responsible
development suggests the immediacy of developing a pathway
forward.
The 2017 Report calls attention to a practical factor in
developing a scientific pathway incorporating genome editing. As
a practical matter, agency regulation, such as that exercised by the
FDA, declines as the application of any scientific breakthrough
"holds the potential for great benefit to individuals, and those
individuals are willing to accept greater risk." 1 7 Specifically, the
Report states that:
As human genome editing improves
technologically, there is every reason to believe that
the health and safety risks to individuals will
diminish. If these risks become de minimis, one
might assume that the potential benefits required to
justify the risks also will decline. Thus, as the
technology improves, its application could extend
from serious illnesses, to less serious illnesses, to
prevention, and in the long term to enhancement,
however defined.8 8
The Report omits a specific reference to germline editing,
but this is implied. This regulatory evolution, which may be
characterized as a slippery slope, is augmented by off-label
prescriptions and transnational applications.
Currently there are a few restrictions on what science may
do. The Report specifies that "there are some genetic alterations
that are insufficiently justified, too risky, or too socially disruptive
to be pursued at this time."'" For example, federal funding for
research using human embryos is prohibited by the Dickey-Wicker
Amendment, although funded research using human embryos
186. Id. at 168-69.
187. Id. atL 151.
188. Id.
189. Id. at 181.
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continues in some states and private research centers.9 o This
federal amendment enacted each year prohibits the use of federal
funds for research involving the creation or destruction of
embryos, and for research putting embryos at risk of injury or
destruction except when necessary to increase their chance for
healthy development.'91 The amendment has been attached to the
annual appropriations bills for the Departments of Health and
Human Services, Labor, and Education since 1996."9
As illustrated by the Dickey-Wicker Amendment,
congressional action centers on embryos; there is no mention of
genome editing or the potential for germline editing.' 93
Prohibiting funding does not curtail research, instead continuing
outside of government supervision that always accompanies
funding.'9 4 The amendment lacks applicability in light of current
scientific developments. The focus of Congress cannot be solely
on the amendment but rather on developing a pathway for the
future."' This future necessitates a congressional inquiry into how
to develop an effective pathway. While important, the human
embryo is only the start of the inquiry. Genome editing and
germline consequences follow because "[tihe intended genome
edits themselves might have unintended consequences which, if
inherited, would also affect descendants."' 9 "[T]he efficiency of
CRISPR/Cas in targeting nuclease-enhanced editing to specific
sites in the genome has raised new vistas including possible human
germline editing."'97 There is also concern over eugenics, the
general respect traditionally afforded human reproductive
190. Id. at 80; see, e.g., 410 ILL. COMP. STAT. ANN. 110/1-50 (West 2019); MONT. CODE
ANN. § 50-11-103 (2017); NEB. REv. STAT. § 28-346, (2016); NEB. REV. STAT. § 71-7606(3)
(2016).
191. HUMAN GENOME EDITING, supra note 27, at 33.
192. Kearl, supra note 33.
193. H.R. 2880, 104th Cong. § 128 (1996).
194. What Is a Grant Manager? (Part 1) Federal Agencies, GRANTS.GOV COMMUNITY BLOG
(Mar. 22, 2017), https://blog.grants.gov/2017/03/22/what-is-a-grant-manager-part-i -fed
eral-agencies.
195. See infra Part III.
196. HUMAN GENOME EDITING, supra note 27, at 188.
197. Id. at 240-41 (detailing that there are alternatives to editing an embryo, such as
editing the eggs or sperm before fertilization, but the issue of the effect upon germline
descendants remains).
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material, and suspicion that human embryo enhancement will
become the overall goal.198
Caution and deliberation permeate both the Report and
resulting recommendations. 199 In addition, "recent history and
current events both undercut this conception of how things do
and should work."2 0 Science is both independent and precedent
of substantive deliberation. Scientific independence was illustrated
in July 2017, when it was announced that the first human embryos
were edited in the United States,20 ' an announcement that was
made prior to gene-edited twin girls born in 2018. Both of these
gene-editing procedures, the latter more aggressive than the
former, occurred independently of governmental regulations or
recommendations. In late 2017, scientists at the Salk Institute
developed a technique to alter the activity, as distinct from the
underlying sequence, of genes associated with disease.20 2
Admittedly, there is a distinction between genome editing on
nonreproductive human cells, called somatic cells, 2 03 and editing
of germline cells. Germline cells are cells that at any point in the
lineage of cells that could give rise to sperm or eggs, which could
fuse during sexual intercourse to create an embryo and thus
continue into the next generation. 204 This latter procedure is
contentious "because the resulting genetic changes could be
inherited by the next generation, and the technology therefore
would cross a line many have viewed as ethically inviolable." 2 0 5
There are other examples, too. Obviously, government
recommendations or funding restrictions are not barriers to
experimentation. Science continues to progress independent from
public discussion and policy formation. Nonetheless, it seems
preferable to make the government more than an observer.
198. Id. at 42, 153, 159.
199. See id.
200. Mahoney & Siegal, supra note 29, at 201.
201. Steve Connor, First Human Embryos Edited in the U.S., MIT TECH. REV. (July 26,
2017), http://www.te4chnologyreview.com/s/608350/first-human-mbryos-edied-in-us.
202. Mahoney & Siegal, supra note 29, at 202 (citing Hsin-Kai Liao et al., In Vivo
Target Gene Activation via CRISPR/Cas9-Mediated Trans-Epigenetic Modulation, 171 CELL
1495 (2017)).
203. HUMAN GENOME EDITING, supra note 27, at 306 (discussing how a somatic cell is
any "ccll of a plant or animal other than a reproductive cell or reproductive cell
precursor").
204. Id. at 299.
205. Id. at 6-7.
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Congress, working with public consensus, needs to establish a
pathway forward.
iii. Regulation
a. Funding versus Sanction
Currently, modification of the human germline is not
prohibited in the United States, however federal funding for this
form of research is forbidden by Congress through the Dickey-
Wicker Amendment." 6 The Congressional prohibition specifies
that none of the funds made available by Congress under the
appropriations act "may be used to notify a sponsor or otherwise
acknowledge receipt of a submission for an exemption for
investigational use of a drug or biological product .. . in research
in which a human embryo is intentionally created or modified to
include a heritable genetic modification."2 0 7 Note that prohibiting
the procedure and prohibiting funding of the procedure are
distinctive, the Amendment doing the latter.20 s Thus, researchers
able to garner private funding may proceed, but private research
may eliminate the public scrutiny which permits evaluation of risk,
morality, and process.2 09 This is a loss for the public.
The National Institutes of Health ("NIH") approved a
proposal for the clinical use of human T-cell editing as a part of a
cancer immunotherapy program. 2 10 Although this proposal is
barred by restrictions on live human embryo research prohibited
by the Dickey-Wicker Amendment, funding resulted from
guidelines prompted by an executive order issued by President
206. See Consolidated Appropriations Act of 2016, Pub. L. No. 114-113, 129 Stat. 2242,
2650 (2015); see also Consolidated Appropriations Act, Pub. L. No. 115-31, 131 Stat. 135,
173 (2017).
207. 129 Stat. at 2283.
208. See 131 Stat. at 173.
209. See, e.g., Zhao, supra note 23, at 127-28. For criminal sanctions imposed on
genetic editing, see for example P.R. Laws Laws Ann. tit. 33, § 4743 (2005) ("Any person
who uses technology to alter the human genome for purposes other than diagnosis,
treatment or scientific research in the field of human biology, particularly genetics or
medicine shall incur a second degree felony.").
210. Seitz, supra note 7, at 70 (citing Sara Reardon, First CRJSPR Clinical Trial Gets
Green Light from US Panel, NATURE (June 22, 2016) http://www.nature.com/news/first-
crispr-clinical-trial-gets-green-llight-from-us-panel-1.20137).
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Obama." These orders resulted in new NIH guidelines that were
established in 2009.212 These revised guidelines permit researchers
to obtain federal funding for human embryo research if: the
embryos were created using IVF for reproductive purposes; the
embryos were voluntarily given by individuals who no longer
needed them; and the embryos were used for research
purposes.2 1 3 It appears that these guidelines apply to CRISPR/Cas
research,214 but the incremental exceptions permitted by the
revised guidelines illustrate the hurdles researchers face when
seeking government funding for newer technologies. Despite the
government hurdles, newer applications of human genome
editing continue. However, Francis Collins, Director of the NIH in
2016, issued a statement affirming that the NIH would not fund
any use of gene-editing technologies in human embryos. 215
Subsequently, in 2017, the National Academy of Sciences and the
National Academy of Medicine both recommended the use of the
existing regulatory infrastructure to evaluate aspects of genome
editing, including possible germline applications, when
compelling reasons presented, based on risk versus benefit
parameters.2 16
A robust public discussion about the values to be
placed on the benefits and risks of heritable
genome editing is needed now so that these values
can be incorporated as appropriate into the
risk/benefit assessments that will precede any
decision about whether to authorize clinical trials
[of human genome editing]. 2
211. See Removing Barriers to Responsible Scientific Research Involving Human Stem
Cells, Executive Order 13505, 74 Fed. Reg. 10,667 (Mar. 9, 2009).
212. See National Institutes of Health Guidelines for Human Stem Cell Research, 74
Fed. Reg. 32,170 (July 7, 2009).
213. Tomlinson, supra note 148, at 457 (citing National Institutes of Health
Guidelines for Human Stem Cell Research, 74 Fed. Reg. 32,170, 32,175 (July 7, 2009)).
214. See Francis S. Collins, Statement on NIH Funding of Research Using Gene-Editing




216. HUMAN GENOME EDITING, supra note 27, at 133-34.
217. Id. at 134.
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Of course, private research continues and often includes
risk/benefit analysis. In 2017, scientists at the Oregon Health and
Science University utilized CRISPR/Cas9 to correct mutations in
the MYBPC3 human gene which leads to sudden death in young
athletes. Human gene "editing was successful in 42 out of 58
human embryos, with 41 of these embryos containing two healthy,
wild-type copies of the MYBPC3 gene." 2 19 Based in part on recent
successes, some predict that the actual editing of humans is only
about ten to twenty years away, 220 but public funding for germline
editing, the most significant hurdle, was placed on hold by the
NIH pending further developments, including more information
about the risks associated with the practice.' Pendency deprives
the government of an active role in planning a value-oriented
pathway.
Private laboratories and scientists may be leery of a
government pathway. Interaction between public versus private
funding pertaining to biotechnology has a history peppered with
federal and state statutes, federal agency regulations, and private
laboratories addressing serious human diseases and thereby
marketing products from which they will derive commercial
benefit.2 2 Congressional prohibitions, such as the Dickey-Wicker
Amendment, are most often noted as illustrative of the barriers
researchers confront because they are singular prohibitions, but
illustrative of systematic restraint.2 23 In addition to Congressional
appropriations amendments, there is a history of regulatory
barriers that have effectively prevented funding of biotechnology
in various settings. 2 24 These barriers are illustrated in the
regulatory pathway.
218. See Hong Ma et al., Correction of a Pathogenic Gene Mutation in Human Embryos, 548
NATURE 413, 418 (2017); Kristina M. Smith, Note, Germline Editing: Two Steps Forward, One
Step Back?, 21 SMU Sci. & TECH. L. REV. 101, 103 (2018) (noting that the first human
germline editing in the world occurred in China in 2015, but it was not considered a
success).
219. Seitz, supra note 7, at 71.
220. Id. at 70-71 (citing Antonia Regalado, Engineering the Perfect Baby, MIT TECH.
REV. (Mar. 5, 2015), http://www.technologyreview.com/s/535661 /engineering-the-perfe
ct-baby).
221. Britt E. Erickson, Editing of Human Embryo Genes Raises Ethics Questions, 93
CHEMISTRY & ENGINEERING NEWS 20, 20-21 (2015).
222. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 62.
223. Id.
224. Id. The statutes and regulations prohibit the Department of Health and Human
Services funding for research, but they do not prohibit the research itself. Id. at 64.
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b. Regulatory Pathway
In 1973, the U.S. Department of Health, Education and
Welfare prohibited research on live human embryos.2 25 Then, in
1974, Congress included within the ban all embryos created
through IVF.2 2 ' Eventually, as science sufficiently progressed so as
to enable genome editing, the NIH created a Recombinant DNA
Advisory Committee to oversee proposals for research funding at
NIH."2 In 1985, that committee recommended against funding
proposals that would involve germline alterations. 2 8 Rather than
focus on embryos and the potential issues relating to human life,
the NIH committee was concerned about germline editing and
the possibility of eugenics, which could propel research into
creating a mythically superior human being.22 9 Admittedly, the
heightened concern over eugenics has a storied background
compiled from a:
[L] ong and troubling history of eugenics ... replete
with dogma that creates hierarchies of human
quality based on race, religion, national origin, and
economic status, and it demonstrates how scientific
concepts, such as natural selection, and public
welfare measures, such as public hygiene, can be
subverted for purposes of cruel and destructive
social policies.23s
Historically, eugenics was associated with breeding of
human beings possessing desired qualities and characteristics with
225. See Miriam Reisman & Katherine T. Adams, Stem Cell Therapy: A Look at Current
Research, Regulations, and Remaining Hurdles, 39 PHARMACY & THERAPEUTICS 846 (2014).
226. Id.
227. COMM. ON THE INDEP. REVIEW & ASSESSMENT OF THE ACTIVITIES OF THE NIH
RECOMBINANT DNA ADVISORY COMM., BD. ON HEALTH SCIS. POLICY, INST. OF MED.,
OVERSIGHT AND REVIEW OF CLINICAL, GENE TRANSFER PROTOCOLS: ASSESSING THE ROLE OF
THE RECOMBINANT DNA ADVISORY COMMITTEE 41-42 (Rebecca N. Lenzi, Bruce M.
Altevogt, Lawrence 0. Gostin eds., 2014).
228. Id. at 50.
229. Id. at 2.
230. HUMAN GENOME EDITING, supra note 27, at 153; see Immigration Act of 1924,
H.R. 7995, 68th Cong. (1924); Buck v. Bell, 274 U.S. 200, 207 (1927) (holding that
sterilization of young women was warranted to prevent degenerate offspring); see also
DANIEL J. KELVES, IN THE NAME OF EUGENICS: GENETICS AND THE USES OF HUMAN
HEREDITY 117-21 (1985).
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the aim to produce a master race.2 3 ' Today, with the ability to edit
the human genome, eugenics can be achieved more efficiently
than breeding of successive generations of human beings."3 The
NIH Committee took note of this.
Although eugenics has a long history, genetically
engineered eugenics, a much newer science, has a short history. In
the 1950s, the structural basis of how DNA duplicates itself was
discovered and people realized that individuals "could be
chemically modified to have 'more' of the 'good' genes."2 33 Since
the early 1950s, scientific advances have fueled the debate over
issues such as permitting enhanced embryos and the possibility
that adults could create "designer babies" that possess what some
think are desired characteristics or qualities.2 " Thus, even though
science may intend to curtail disease, eventually the technology
can address more cosmetic characteristics.
Concern arises over permitting parents to "bioengineer
children" through "genetic enhancement, which might ultimately
allow parents to produce physically and intellectually superior
children."2 35 Not just beautiful children, but children that are
stronger in mind and body.3 Some argue that because this
technology is only available to the wealthy, unequal access to
embryo enhancement would widen societal divisions. In 2017,
the American Society of Human Genetics (ASHG) published a
statement on germline editing to address these concerns.23 8
Overall, the ASHG's statement supports public funding for
research on possible future clinical applications of gene editing,
but suggests that such research must be based on a compelling
medical rationale, evidence that supports its clinical use, an ethical
justification, and a transparent public process to solicit and
231. Eugenics, HISTORY (Aug. 21, 2018), https://www.history.com/topics/germany/
eugenics. Recall the fanatical racial goals of Adolf Hitler for one example of the dangers
of eugenics. Id.
232. See id.
233. HUMAN GENOME EDITING, supra note 27, at 155; James D. Watson & Francis H.
Crick, Molecular Structure ofNucleic Acids, 171 NATURE 737, 737-38 (1953).
234. See, e.g., Sas & Lawrenz, supra note 7.
235. Zalesne, supra note 52, at 455.
236. See id.
237. Id.
238. Kelly E. Ormond et al., Human Germline Genome Editing, 101 AM. J. HUM.
GENETICS 167, 167 (2017).
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incorporate public input.23 9 It is easy to notice the variety of
interested parties, each having an opinion on the matter, which
suggests the need for public input and engagement.
But while some see risk in genetic editing, others dismiss
the "designer baby" concern and focus solely on the possibility to
eliminate heritable human disease. Others argue that eugenics
and freedom from disease are irrelevant. The single focus should
be upon an adult's individual reproductive liberty and
concomitant privacy entitlement. Proponents of this argument
assert that the starting point on any discussion of genome editing
should be an adult's reproductive freedom.24 ' The people voicing
the call for reproductive freedom argue "that the burden is on the
state to articulate an identifiable harm to identifiable persons in its
justification for prohibiting the conduct of private parties, not on
the private parties to articulate why their conduct is morally
permissible." 24 2
Since 1974 seven national commissions have been formed
to discuss bioethical issues.2 43 One of these, a 1982 presidential
commission, wrote in its conclusions that it found no ground for
concluding that any current or planned form of genetic
engineering was intrinsically wrong or irreligious per se.244 Then,
in 2001, a federal bioethics commission was created to focus not
on costs or benefits associated with bioethics, but rather on
parents' ultimate control over their children.245 The commission's
concern was "that germline enhancement might encourage
people to view children as something to be designed and
239. Id. at 173.
240. Zalesne, supra note 52, at 459.
241. Id. at 460.
242. Id.
243. HUMAN GENOME EDITING, supra note 27, at 172 (citing various commissions:
National Commission for the Protection of Human Subjects of Biomedical and Behavioral
Research (1974-1978), President's Commission for the Study of Ethical Problems in
Medicine and in Biomedical and Behavioral Research (1978-1983), Biomedical Ethical
Advisory Committee (1988-1990), Advisory Committee on Human Radiation Experiments
(1994-1995), National Bioethics Advisory Commission (1996-2001), President's Council
on Bioethics (2001-2009), and Presidential Commission for the Study of Bioethical Issues
(2009-2016)).
244. PRESIDENT'S COMM'N FOR THE STUDY OF ETHICAL PROBLEMS IN MED. &
BIOMEDICAL & BEHAVIORAL RESEARCH, SPLICING LIFE: A REPORT ON THE SOCIAL AND
ETHICAL ISSUES OF GENETIC ENGINEERING WITH HUMAN BEINGS 77 (1982).
245. HUMAN GENOME EDITING, supra note 27, at 157.
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manipulated."" The commission's discussion of the best interest
of the child, rather than the reproductive rights of the adult,
provide a different approach to individual liberty interests.24 7
There is an important development that has repercussions
today. In 1986 the White House Office of Science and Technology
Policy ("OSTP") gave regulatory authority over biotechnology to a
troika of three federal agencies.24  The action created what is
called the Coordinated Framework,24 9 an important factor in
regulating bioethics today. The three federal agencies comprising
the Coordinated Framework are the FDA, the Environmental
Protection Agency ("EPA"), and the U.S. Department of
Agriculture ("USDA") .2o Few commentators on bioethics gave
serious thought to the Coordinated Framework until Americans
became concerned about genome editing and food production, a
regulatory process entrusted to the USDA. 25 1 Likewise, the EPA
became the subject of public attention when James Clapper,
former United States Director of National Intelligence, identified
genome editing as a weapon of mass destruction and
proliferation.25 2 In tandem with concerns raised by James Clapper,
the 2017 Departments of Health and Human Services, Labor, and
Education Appropriations Bill included an amendment that
required the Office of the Director of National Intelligence to
246. Id. But see Zalesne, supra note 52, at 455 (noting that parents have always sought
to improve their children).
247. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 138 ("Consent by
intended parent(s) to a process that would result in the birth of a child through MRT
could not fully protect the interests and welfare of future children.").
248. Christine C. Vito, State Biotechnology Oversight: The Juncture of Technology, Law, and
Public Policy, 45 ME. L. REV. 329, 335 (1993).
249. Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. 23,302
(June 26, 1986).
250. For more information on regulating animal research, see 1966 Animal Welfare
Act, 7 U.S.C. § 2131, enforced by the US Department of Agriculture; Federal Food, Drug,
and Cosmetic Act, 21 U.S.C. § 321 (f), (g), (s), and (rr) (1938). For more information on
genetically engineered food, see Mike Orcutt, Who Approved the Genetically Engineered Foods
Coming to Your Plate? No One., MIT TECH. REv. (Apr. 21, 2016), https://www.technology
review.com/s/601295/who-approved-the-genetically-engineered-foods-coming-to-your-pla
te-no-one.
251. Brooke Borel, The U.S. Regulations for Biotechnology Are Woefully Out of Date, SLATE
(Apr. 21, 2017), http://www.slatc.com/articles/technology/future-tense/2017/ 04?u s
biotechnology-regulationsarewofefully-otof..date.html.
252. Antonio Regalado, Top U.S. Intelligence Official Calls Gene Editing a WMD Threat,
MIT TECH. REv. (Feb. 9, 2016), https://www.technology review.com/s/600774/top-us-int
elligence-official-calls-gene-editing-a-wmd-threat.
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formulate a plan to "'monitor advances in life sciences and
biotechnology that addresses ... [United States] competitiveness
in the global bio-economy and the risks and threats in genetic
editing technologies,' such as CRISPR.""
Today, as human genome editing becomes increasingly
possible, the FDA has become the focus of scrutiny because it has
regulatory responsibility for, among other procedures, genome
editing."' "The FDA, as the sole federal regulatory agency for
biomedical products in the United States, focuses on safety and
efficacy when evaluating gene-transfer products, from the first
time they are used in humans through their commercial
distribution and over the lifetime of their use."' Indeed, clinical
testing of somatic cell genome editing could not begin in the
United States without the FDA's first approving an Investigational
New Drug ("IND") application, and the clinical protocol would
require institutional review board ("IRB") approval and ongoing
review.' The IND applications for gene therapy are regulated by
the Office of Tissues and Advanced Therapies (Previously the
Office of Cellular, Tissue and Gene Therapies) within the Center
for Biologics Evaluation and Research ("CBER") .25' Any Human
Genome editing products may benefit from accelerated review by
the FDA under the 21st Century Cures Act, 2 8 signed into law in
December 2016.
The Obama administration was concerned that the
Coordinated Framework, which was established in 1986, was not
evolving sufficiently to address current technological advances,
thus creating regulatory confusion and lost opportunities."
Hence, in 2015, the White House directed the Office of Science
and Technology "to update the Coordinated Framework to ensure
that the Framework was modernized and prepared for future
253. Smith, supra note 218, at 105 (citing Consolidated Appropriations Act, Pub. L.
No. 115-31, § 606, 31 Stat. 832, (2017)).
254. HUMAN GENOME EDITING, supra note 27, at 56.
255. Id. (citation omitted). For a summary of the regulatory pathway for a medical
product created using genome editing, see id. at 36-37.
256. Smith, supra note 218, at 103.
257. HUMAN GENOME EDITING, supra note 27, at5l.
258. Regenerative Medicine Advanced Therapy Designation, U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducs/ucm 5 3 7 6 7
0.htm (last visited Mar. 22, 2019) (describing how a drug is eligible for regenerative
medicine advanced therapy designation under the 21st Century Cures Act).
259. Borel, supra note 251.
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biotechnological advancements." 2 o Specifically, the OSTP wanted
to modernize the Coordinated Framework to clarify "the
mechanism and timeline for regularly reviewing, and updating as
appropriate, the [Coordinated Framework] to minimize delays,
support innovation, protect health and the environment, and
promote the public trust in the regulatory systems for
biotechnology products."2 6 ' The update is still underway and the
outcome far from conclusive. Meanwhile, there are those who
contend that "the irony of subjecting groundbreaking scientific
discoveries to an archaic regulatory scheme is causing many
researchers to lose faith in the system."26 2 The only solution for
some is for Congress to enact legislation authorizing the creation
of a new regulatory agency focused specifically on the oversight of
reproductive and genetic biotechnologies .2 6  There is a sense of
urgency too. "The dearth of IVF and biotech competent countries
with adequate legislation for genetic modification of humans is
troubling. Countries need to modernize their legislative and
regulatory systems to ensure that premature use of [technology] in
the human germline is prevented, saving the collective human
genome from future cataclysm. "26
As stated, each federal agency within the Coordinated
Framework has individual responsibilities. The FDA has regulatory
authority over cell and gene therapy products marketed to the
public."' "Human embryo research clearly falls outside the
purview of [agriculture] and [the environment], and the FDA is
currently blocked from even considering proposals that involve
human embryo research at this point."2 66 This prohibition results
from the wording of the Dickey-Wicker Amendment.2 6 7 However,
260. Cormier & Carvajal, supra note 137, at 9; see also Borel, supra note 251.
261. Cormier & Carvajal, supra note 137, at 9 (citing 80 Fed. Reg. 62,540 (Oct 16,
2015)).
262. Tomlinson, supra note 148, at 461 (citingJennifer Kuzma, A Missed Opportunity
for U.S. Biotechnology Regulation, SCIENCE, Sept. 16, 2016, at 1211).
263. See Zhao, supra note 209, at 137.
264. Jason Glanzer, The Human Germline Modification Index: An International Risk
Assessment for the Production of Genetically Modified Humans, 9 CREIGHTON INT'L & COMP. L.J.
68, 86 (2017).
265. Tomlinson, supra note 148, at 458.
266. Id. at 475. See also HUMAN GENOME EDITING, supra note 27, at 43 ("A single-cell
fertilized egg is treated as if it were an embryo for most relevant state and federal laws,
and restrictions on the work or on the funding would apply.").
267. Tomlinson, supra note 148, at 456.
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government-regulated in vitro research is currently underway in
China, using nonviable embryos, and research has been approved
using viable embryos in Sweden and the United Kingdom.2 18 Of
course, there are parallel privately funded research projects.
In the United States, "[w]ere a company to seek approval
of use of CRISPR/Cas directly administered to a patient, [the]
FDA would likely conclude that the targeting sequence/nuclease
complex is a biological product subject to regulation in FDA's
Center for Biologics Evaluation and Research (CBER) "269 Then,
"[m]arketing authorization would depend on the company
demonstrating that the specific CRISPR/Cas complex can be
reliably and consistently manufactured, is safe to use, and has its
intended effect on the human patient." 27 0 The 1994 NIH Human
Embryo Research Panel concluded that research creating embryos
for research is justified if there is no alternative and the research is
"potentially of outstanding scientific and therapeutic value."27' If
these guidelines are applicable, it would appear that "the genome-
editing research necessary to test edited gametes would seem to
fall within this exception. "272 However, the NIH is not the FDA,
and this research responsibility lies with the FDA under the
Coordinated Framework.
c. Food and Drug Administration
To date, the FDA and its CBER "has never approved a
proposal to modify the germline," 274 or approved any gene editing
product,275 although it has authorized a number of gene therapy
trials.27 ' But the FDA has not yet approved a gene therapy for
market.2 77 When the FDA scientific advisory committee reviews a
268. HUMAN GENOME EDITING, supra note 27, at 41-42.
269. Cormier & Carvajal, supra note 137, at 7; see also 42 U.S.C. § 262(a) (2012);
Elizabeth C. Price, Does the FDA Have Authority to Regulate Human Cloning?, 11 HARV.J.L. &
TECH 619 (1998).
270. Cormier & Carvajal, supra note 137, at 7.
271. HUMAN GENOME EDITING, supra note 27, at 44.
272. Id.
273. Coordinated Framework for Regulation of Biotechnology, 51 Fed Reg. 23,302,
23,304 (June 26, 1986).
274. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 62.
275. Cormier & Carvajal, supra note 137, at 7-8.
276. Is Gene Therapy Available to Treat My Disorder?, U.S. NAT'L LIBR. MED. (Feb. 26,
2019), https://ghr.nim.nih.gov/primer/therapy/availability.
277. HUMAN GENOME EDITING, supra note 27, at 35.
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gene therapy or genome-editing protocol, the committee meeting
is open to the public, and a public representative must be
included among the advisory members.7 Were a company to seek
approval of CRISPR/Cas directly administered to a patient, FDA
would likely treat this as a biological product subject to regulation
in the FDA's Center for Biologics Evaluation and Research.7
Upon review, CBER would want to know if CRISPR/Cas were
targeted sufficiently so that no "untoward off-target effects would
be observed."28 ' But if the CRISPR/Cas complex is used to edit
genomes, then regulation would depend upon whether the cells
are within the human body or have been removed.28 ' The latter
process would have an easier and a shortened review compared to
the former.8 Furthermore, any laboratory seeking approval from
the FDA "will have an added burden of educating the FDA, and of
wading against the natural precautionary tendencies of an agency
faced with a high-profile and unproven technology. "283
Today the focus of regulatory bodies, such as the FDA, is
upon the distinction between prevention of disease and personal
physical enhancement, the former receiving attention and
funding if the primary goal is to lessen the impact of any
disease.8 4 However, the latter, involving cosmetic or performance-
enhancement, will be denied funding unless approved by the
Recombinant DNA Advisory Committee ("RA"), the institutional
biosafety committees ("IBC"s), and the IRBs."8 One commentator
278. Federal regulations require that an Institutional Review Board include experts
with appropriate technical training, and "at least one member whose primary concern is
in a nonscientific area and one lay member who is not otherwise affiliated with the
institution." See id. at 46.
279. Cormier & Carvajal, supra note 137, at 7.
280. Id. at 8.
281. Id.
282. Id. Removed or stored human specimens are protected under the Common Rule
that governs federal agencies and departments, effective January 2018. See, e.g., Federal
Policy for the Protection of Human Subjects, 82 Fed. Reg. 7,149, 7,150 (Jan. 19, 2017)
(noting that "exempt research would be required to undergo limited [Institutional
Review Board] review to ensure that there are adequate privacy safeguards for identifiable
private information and identifiable biospecimens").
283. Cormier & Carvajal, supra note 137, at 10.
284. See Seitz, supra note 7, at 84; The FDA Supports Research to Reduce Health Disparities,
U.S. FOOD & DRuG ADMIN., https://www.fda.gov/ForConsumers/ConsumerUpdates/u
cm404387.htm (last updated Apr. 19, 2017) (explaining that FDA uses data from clinical
trials to determine whether medical products are safe and effective for disease treatment).
285. HUMAN GENOME EDITING, supra note 27, at 169.
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suggests that it is permissible to retain the Coordinated
Framework and the Congressional Dickey-Wicker Amendment
forbidding funding to pay for research in which a human embryo
is intentionally created or modified to include a heritable genetic
modification."' What is needed, the commentator argues, is "a
specific exception or exceptions, such as those that would allow
the FDA to receive and review [IND] applications for the use of
[human germline modification] to treat specific monogenic
diseases." 8 7  Specifically, the commentator argues, the
Congressional rider on the Consolidated Appropriations Act
would permit an exception for:
[A] submission pertaining to the treatment of
embryos where there is a substantial risk that the
child will be born with a severe or life-threating
genetic disease, where the disease has a well-
established and specific genetic cause, where the
modification results in wild-type gene, and where
the patients could not obtain equally effective
treatment using other means.28 8
Perhaps what is needed is a more comprehensive scientific
pathway to accommodate the increasing scientific developments,
particularly a pathway that results from greater access to public
opinion.
Eventually "progress will be necessary before any genome-
editing intervention for indications other than the treatment or
prevention of disease or disability can satisfy the risk/benefit
standards for initiating a clinical trial [involving gene editing]."289
Federal regulators take a cautionary approach. An illustration is
the approval of the human growth hormone ("hGH"), which
became the focus of discussion in 1985.29o The issue revolved
286. See Seitz, supra note 7, at 75-76.
287. Id. at 80.
288. Id. at 91. For a definition of what constitutes a serious disease, see 21 C.F.R. §
312.300(b) (1) (2018).
289. HUMAN GENOME EDITING, supra note 27, at 159 (noting that this is true for both
somatic and heritable germline editing). One author argues that Congress should permit
funding for human genome editing if it will address severe genetic diseases that have no
better alternative. See Seitz, supra note 7, at 61.
290. See HUMAN GENOME EDITING, supra note 27, at 160.
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around whether giving the hormone to children or adults
constituted treatment, prevention, or enhancement, and which of
these uses might be appropriate.2 9 ' Eventually, the FDA approved
hGH for use in children and adults, but only for a narrowly
defined list of diseases involving stature.29 2 Caution was illustrated
in the FDA's restricted use of the growth hormone hGH.2 11
Initially, the FDA did not prevent "off-label" use of the drug for
enhancement purposes, but increasingly the drug was used for
unintended purposes such as antiaging or enhancement of
athletic performance.2 9 4 As a result, Congress enacted the Crime
Control Act of 1990,295 which prohibits any person from knowingly
distributing or possessing human grown hormone intending to
use it for any purpose not unauthorized by the Secretary of Health
and Human Services.29 6 Conviction for a violation is considered a
felony, punishable by fines and up to ten years in prison.
Currently, legislative and public policy forums relating to
human embryonic research are characterized by cautious
dialogue, scientific reports, and rejections of government funded
research.29 8 However, there are those who argue that "hitting the
pause button on human germline editing may not be as viable an
option as its proponents assume... . [B]roken momentum means
lost opportunities."" During this status quo, research continues
unabated in the private community, bolstered by the
independence of the independently funded laboratories arguing
291. Id.; see also David B. Allen & Leona Cuttler, Treatment of Short Stature, 368 NEW
ENG.J. MED. 1220 (2013).
292. See Vageesh S. Ayyar, History of Growth Hormone Therapy, 15 INDIAN J.
ENDOCRINOLOGY & METABOLISM, S162 (2011).
293. See HUMAN GENOME EDITING, supra note 27, at 160.
294. Brian Wu, What Do Growth Hormone Injections Do?, MED. NEWS TODAY (Jan. 18,
2019), https://www.medicalnewstoday.com/articles/312905.php.
295. 21 U.S.C. § 333(e) (2018); see also Ryan Cronin, Bureaucrats vs. Physicians: Have
Doctors Been Strpped of Their Power to Determine the Proper Use of Human Growth Hormone in
Treating Adult Disease?, 27 WASH. U.J.L. & POL'Y 191 (2008).
296. 21 U.S.C. § 333(e) (2018).
297. Id.
298. Richard Adams, Government Funding for Stem Cell Research Blocked by US Court,
GUARDIAN (Aug. 23, 2010, 10:00 PM), https://www.theguardian.com/world/richard-
adams-blog/2010/aug/24/stem-cells-research-us-funding-blocked.
299. Mahoney & Siegal, supra note 29, at 206.
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both freedom from "devastating genetic diseases,"300 and the
advantageous financial incentives that would result were these
breakthroughs to be realized. The ability to argue for betterment
of the human race trumps any cautionary tales of eugenics or
inadequacy of consent.
We live in an age of medical tourism, which means that
researchers are able to utilize foreign locations "for faster and
cheaper therapeutic options, as well as newer or less regulated
interventions, [which] will be impossible to control completely if
the technical capabilities exist in more permissive jurisdictions. "301
The financial benefits will be extraordinary if successfully
harnessed by a global pharmaceutical company. Indeed, studies
suggest that in our interconnected world the medical tourism
market is currently worth more than $61 million, with every
expectation this market will continue to expand.30 2 Also, the rise
in the number of assisted reproductive procedures, IVF, and
professional clinics throughout the world suggests both a need
and a market for the types of services offered pertaining to
genome editing.
Transnational regulation is public, but ineffective. For
example, in 2015 the Council of Europe's Convention on Human
Rights and Biomedicine and UNESCO's Universal Declaration on
the Human Genome and Human Rights wrote that germline
modification would jeopardize the inherent and therefore equal
dignity of all human beings and renew eugenics.os The Council of
Europe's Oviedo Convention "specifically calls for a prohibition
on the use of genetic engineering of the germline or changing the
makeup of the following generations."o3  Also, every nation in the
European Union has adopted the EU Directive on Clinical Trials,
which "requires member states to adopt a system for the review of
clinical research consistent with internationally recognized
300. Id.; see also Donald B. Kohn et al., Ethical and Regulatory Aspects of Genome Editing,
127 BLOOD 2553, 2554 (2016); PHILIP KITCHER, THE LIVES TO COME: THE GENETIC
REVOLUTION AND HUMAN POSSIBILITIES 65 (1996).
301. HUMAN GENOME EDITING, supra note 27, at 190.
302. SeeJessica Cussins & Leah Lowthrop, Germline Modification and Policymaking: The
Relationship Between Mitochondrial Replacement and Gene Editing, 24 NEW BIOETHICS 74, 87
(2018).
303. See U.N. EDUC., SC., & CULTURAL ORG., REPORT OF THE IBC ON UPDATING ITS
REFLECTION ON THE HUMAN GENOME AND HUMAN RIGHTS (2015), http://unesdoc.un
esco.org/images/0023/002332/233258E.pdf.
304. HUMAN GENOME EDITING, supra note 27, at 263.
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standards for good clinical practice for the ethical and
scientifically valid design, conduct, and report of trials."o3 0 Chinese
agencies have published regulatory guidelines for human embryo
research and IVF practices.so0 Finally, some countries and locales,
such as Mexico City, Panama, and Columbia, provide criminal
penalties for those using genetic manipulation for any reason
other than for the elimination or treatment of a serious defect or
disease. But attempts at uniformity of regulation only illustrates
the complexity of control and the shortcomings of government
regulation. And successful human gene editing procedures in
each of these nations belittles any claim to effectiveness of control.
Because nations have different historical, economic, social,
and cultural systems and values, "reaching consensus among 100
or more nations on regulatory requirements for any technology is
a laborious and resource-intensive undertaking that in the end
may not be successful.""3  Instead, the Human Genome Editing
Report published by the American National Academies of Science
suggests that a better goal is to foster international cooperation
and coordination so as to develop common ground that permits a
balance between innovation and precaution."' Such language, as
found in the Human Genome Editing Report, suggests developing
a pathway based in transparency and consultation, rather than
fixed approval or disapproval.
International cooperation was evident in 2016, when the
International Society for Stem Cell Research ("ISSCR") published
305. Id. at 266 (citing Wing May Kong, The Regulation of Gene Therapy Research in
Competent Adult Patients, Today and Tomorrow: Implication of EU Directive 2001/20/EC, 12
MED. L. REV. 164--80 (2004)). The FDA participated in the international process that
developed these standards and publishes them as guideline documents. See SOPP 8101.1:
REGULATORY MEETINGS WITH SPONSORS AND APPLICANTS FOR DRUGS AND BIOLOGICAL
PRODUCTS (2017), http://www.fda.Gov/BiologicsBloodVaccines/GuidanceComplianceR
egulatorylnformation/ProcedurcsSOPPs/ucm079448.htm.
306. See People's Republic of China, Ministry of Health, Guidelines on Human
Embryonic Stem Cell Research, CHINA NAT'L CTR. BIOTECHNOLOGY DEV. (July 15, 2014),
http://www.cncbd.org.cn/News/Detail/3376.
307. C6digo Penal para el Distrito Federal, arts. 145, 154, Gaceta Oficial del Distrito
Federal 16-07-2002 (Mex.).
308. HUMAN GENOME EDITING, supra note 27, at 268.
309. Id. at 269; see also Public Engagement in Responsible Research and Innovation,
EUROPEAN COMM. (2016), http://ec.europa.eu/programmes/horizon202O/en/h2020-sec
tion/public-engagement-responsible-research-and-innovation; Voices, EUROPEAN COMM.
(2016), h ttp://www.ecsite.eu/activities-and-services/projects/ voices; ORG. FOR ECON. Co-
OPERATION & DEV., INTERNATIONAL. REGULATORY CO-OPERATION: ADDRESSING GLOBAL
CHALLENGES 15-17 (2013).
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a statement: "Until further clarity emerges on both scientific and
ethical fronts, the ISSCR holds that any attempt to modify the
nuclear genome of human embryos for the purpose of human
reproduction is premature and should be prohibited at this
time."31 Similarly, an international group of experts suggested
that heritable genome editing "might be acceptable," but
suggested that a number of safety, efficacy and cultural attitudes
should be explored prior to approval."' Illustrative of this
cautionary approach is the British Nuffield Council on Bioethics;
it concluded in its 2018 report that in reference to genome editing
technologies, categorical limits should not be imposed "if such
experiments would not be biologically reckless and they would be
consistent with the welfare of future people, not socially divisive
and not initiated without prior societal debate, they would not
unnecessarily undermine the concept of human rights or the
rights of the future individual concerned."3 1 2
Amidst competing arguments over all elements of genome
editing, the reality of the immense monetary gains that may be
made from the procedure is likely to moot any obstacles. To
illustrate, "[i]n May 2017, MarketsandMarkets published a report
predicting that the genome editing market will be worth $3.5
billion in just four years.""' As further illustration of the promise
of commercialization, in Boston, three start-up companies
partnered with pharmaceutical companies such as Bayer and
Novartis and raised an aggregate $1 billion to address the
possibilities inherent in genome editing.314 The prediction is that
genome editing may be "sold as an 'add-on' at fertility clinics,"315
where couples or individuals could purchase genome editing
options, establishing a system of consumer-based eugenics for
those able to afford it. As summarized in a 2018 report by the
310. HUMAN GENOME EDITING, supra note 27, at 133 (citing INT'L SOC'Y FOR STEM
CELL RESEARCH, GUIDELINES FOR STEM CELL RESEARCH AND CLINICAL. TRANSlATION 8
(2016), http://www.isscr.org/docs/default-sourcc/guidclines/isscr-guidelines-for-stCM-
cell-research-and-clinical-translation.pdf sfvrsh=2).
311. HUMAN GENOME EDITING, supra note 27, at 133 (citing HINXTON GRP.,
STATEMENT ON GENOME EDITING TECHNOLOGIES AND HUMAN GERMLINE GENETIC
MODIFICATION 2 (2015), http://www.hinxtongroup.org/hinxton2015 statement.pdf.
312. NUFFIEID COUNCIL ON BIOETHICS, supra note 14, at 97.
313. Bos. Coll. Law Review Staff, Note, The Price Tag on Designer Babies: Market Share
Liability, 59 B.C. L. REV. 319, 328 (2018).
314. Id.
315. Cussins & Lowthrop, supra note 302, at 88.
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Nuffield Council on Bioethics, " [m] any interest groups sustained
either by patients themselves or by pharmaceutical companies
offer strong advocacy for the funding and development of new
treatments for genetic diseases, including the extension of
reproductive options."3 16
D. After IVF Mitochondrial Replacement Transfer
i. The Science
Mitochondrial replacement transfer ("MRT") is a new
technique, evolving from IVF and the expansion of ART.' It is a
form of editing that carries with it significant ethical, moral,
technological, and legal issues because it could introduce
permanent and heritable changes to the human gene pool."' By
editing a defective oocyte (egg) or a zygote (fertilized oocyte) in
females, the modification in the DNA could result in heritable
change; the effects of this are unknown and therefore a cause for
concern."' In its 2016 Report, the National Academies of Sciences
concluded that there are several inherent complexities associated
with mitochondrial genetics. 2 1 "Overall, these complexities
underscore the relatively unpredictable nature of mitochondrial
genetics, which could complicate the ability of preclinical studies
to predict with certainty the safety and efficacy of MRT in
humans." 2 1
As with genome editing, MRT makes possible eradicating a
disease for which there is no known cure, but the effects of which
316. NUFFIELD COUNCIL ON BIOETHICS, supra note 14, at 18.
317. Cussins & Lowthrop, supra note 302, at 74.
318. See id. MRT and genome editing are considerably different in technical terms.
The first recombines intact sequences of mitochondrial DNA and nuclear DNA in novel
biological constructs, while the second makes changes to nuclear DNA sequences
themselves. Id. at 76.
319. See MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 6-7; Robert
Kiltzman et al., Controversies Concerning Mitochondrial Replacement Therapy, 103 FERTILITY &
STERILITY 344, 344-45 (2015), https://www.ncbi.nim.nih.gov/pmc/articles/PMC45059
24/pdf/nihms-648296.pdf.
320. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 6-7.
321. Id. at 54. Specifically, uncertainties of MRT research involve: (1) limitations of
current animal and in vitro models, as well as available data for purposes of predicting
safety and efficacy; (2) uncertainty of techniques involved for validating efficacy of MRT-
namely for quantifying pathogenic mtDNA carryover and heteroplasmy load; and (3) the
potential for yet unknown adverse effects of reagents and manipulations employed in
MRT on the resulting embryo, fetus, or future child. Id. at 57.
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may affect a human brain, muscles, heart, gastrointestinal tract,
and liver.' 22 As a result of recent scientific discoveries, specifically
the gene editing tool, CRISPR, it is possible to "remov[e] the
nuclear DNA from the target egg's defective mtDNA and [place] it
within a donated egg with healthy mtDNA. The nuclear DNA of
the donated egg is similarly removed so that the healthy mtDNA is
the only contribution by the donor."1 2 3 The procedure will not
help those already born and suffering from mitochondrial disease,
but it does prevent a second-generation transmission of mtDNA-
based diseases. 324 These significant diseases may be circumvented
while at the same time permitting an affected mother to have
genetically related children.
The procedure was used successfully with the birth of a
baby boy in 2016. Dr. John Zhang, of the New York New Hope
Fertility Center, worked with a couple from Jordan and then
traveled to Mexico, performing a "maternal spindle transfer." 25
Eventually, on April 6, 2016, a healthy baby boy was born to the
Jordanian couple in Mexico City.32 ' There have been other reports
of MRT being used by a physician in Kiev, Ukraine, to correct "the
problem" and allow a patient to give birth to a healthy baby
genetically her own. 2 ' After the birth in Mexico, the British
Parliament voted to permit a MRT exception to a policy in the
United Kingdom prohibiting human germline editing, a policy
shared with an additional thirty-eight countries that have such a
ban.3 2 ' There is no such exception in the United States, which
prohibits funding for "research in which a human embryo is
intentionally created or modified to include a heritable genetic
modification. "329
322. Id. at 37.
323. Zhao, supra note 23, at 123-24.
324. Id.
325. Katherine Drabiak, Emerging Governance of Mitochondrial Replacement Therapy:
Assessing Coherence Between Scientific Evidence and Policy Outcomes, 20 DEPAUL J. HEALTH
CARE L. 1 (2018).
326. Hamzelou, supra note 26; see also Cesar Palacios-Gonzalez & Maria de Jesus
Medina-Arellano, Mitochondrial Replacement Techniques and Mexico's Rule of Law: On the
Legality of the First Maternal Spindle Transfer Case, 4J.L. & BIOSCIENCES 50-69 (2017).
327. Drabiak, supra note 325, at 1-2.
328. See Michael Le Page, UK Becomes First Country to Give Go Ahead to Three-Parent
Babies, NEW SCIENTIST (Dec. 15, 2016), https://www.newscientist.com/article/211 6 4 0 7 -u
k-becomes-first-countiy-to-give-go-ahead-to-three-parent-babies.
329. Consolidated Appropriations Act of 2016, Pub. L. No. 114-13, § 749, 129 Stat.
2242, 2283 (2015).
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The National Academies of Sciences, Engineering and
Medicine wrote in 2016 that four scientific events occur as a result
of MRT.sso First, embryos may be created that, if taken to term,
would result in offspring with genetic material from three
different persons, including two women of different maternal
lineage.3 1 Second, a mitochondrial transfer would constitute a
genetic modification that could be passed down through future
generations if the offspring were female.3 32 Third, any genetic
modification made today could have future unknown effects,
which would not be reversible.s3 And fourth, any genetic
modification would affect every cell type of the resulting
individual, thus affecting the total organism rather than being
confined to a specific organ system.3 3' Like human genome
editing, MRT could enable heritable genetic modification, a
historic development.3 3 1 It also "irrevocably alters the face of
assisted reproduction from a discipline focused on infertility to
one with a far broader portfolio." 3 ' This fact is significant as MRT
may be another element in the list of options available at current
and future fertility clinics throughout the United States and the
other advanced nations of the world.
To date, no federal or state regulatory authority of the
United States has received an application to pursue a cytoplasm
transfer technique such as MRT; thus, no approval has been given
for "a cell-based product that involves genetic material from two
women of different maternal lineages."337 However, in spite of the
lack of explicit approval, the National Academies of Sciences
Report, after extensive investigation and public involvement,
"concludes that it is ethically permissible to conduct clinical
investigations of MRT, subject to certain conditions and principles
330. MITOCHOND)RILm REPLACEMENT TECHNIQUES, supra note 43, at xiii-xiv.
331. Id.
332. Id. at xiv.
333. Id.
334. Id.
335. Zhao, supra note 23, at 122 (citing Eli Y. Adashi, Fi Years After Huxley: The
Roadmap of Reproductive Medicine Revisited and Updated: The 2015 SRI-Pardi Distinguished
Scientist Plenary Lecture of the Society for Reproductive Investigation, 22 REPROD. SCiS. 1330,
1332 (2015)).
336. Id. (citing Adashi, supra note 335, at 1332).
337. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at xii-xiv, n.2.
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laid out in [its] report.""' Specifically, the report states that the
primary focus should be the best interest of any child born as a
result of MRT: "Clinical investigation should collect long-term
information regarding psychological and social effects on children
born as a result of MRT, including their perceptions about their
identity, ancestry, and kinship."339
In addition, clinical investigations should be limited to
women who may potentially transmit serious mtDNA disease, and
also to transfer only male embryos for gestation so as to avoid
introducing heritable genetic modification during initial clinical
investigations. 340 Using male embryos rather than female embryos
would prevent introducing heritable genetic modifications, but
the FDA's Cellular, Tissue and Gene Therapies Advisory
Committee recommends using female embryos when three
conditions have been met. First, there is compelling evidence of
safety and efficacy in use of the procedure in male embryos;
second, there is preclinical animal research showing evidence of
intergenerational safety and efficacy; and third, an existing shared
framework, including international research, concerning the
acceptability of, and moral limits on, heritable modification.
Interestingly, the United Kingdom Human Fertilisation and
Embryology Authority ("HFEA") takes a position against any male-
embryos-only policy,3 42  thereby countenancing heritable
modification. The British Authority's rationale is that using sex
selection after MRT would expose the embryos to gender
selection, an additional intervention that might generate extra
risk.3 4 3
Even though the National Academies of Sciences
recommends clinical investigations, there is an absence of
governmental approval. Indeed, similar to genome editing, there
338. Id. at xv. ("The committee concludes that the most germane ethical, social, and
policy considerations associated with MRT could be avoided through limitations on the
use of MRT or are blunted by meaningful differences between the heritable genetic
modification of nDNA and that introduced by MRT.").
339. Id. at 12. "In assessing the ethics of the balance of benefits and risks in MRT
clinical investigations, minimizing the risk of harm to the child born as a result of MRT is
the primary value to be considered." Id. at 116.
340. Id. at xv.
341. Id. at 131.
342. AinsleyJ. Newson et al., Ethical and Legal Issues in Mitochondrial Transfer, 8 EMBO
MOLECULAR MED. 589, 590 (2016).
343. Id.
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is sufficient government policy in place that would hinder, if not
prohibit MRT.3" And yet, like genome editing, MRT is a reality."
Both procedures complement the greater availability of assisted
reproduction and both are likely to garner increasing public
support. This, together with the encouragement of
pharmaceutical companies, suggest that the issue of how
government should respond is imminent.
ii. Public Discussion
Public support for human genome editing and for MRT is
derived from the possibility that each may be an effective means to
prevent the transmission of heritable disease. mtDNA diseases,
correctable through MRT, "vary in presentation and severity, but
common symptoms include developmental delays, seizures,
weakness and fatigue, muscle weakness, vision loss, and heart
problems."3" Any of these diseases, alone or in tandem, may lead
to morbidity and in some cases premature death.34 7 However,
through MRT a woman may have a healthy, genetically related
child, and may never see her child suffer."'
Not all commentators find that the promise of eliminating
serious disease warrants the resources necessary for MRT. Some
argue that mitochondrial disease incidence is too rare to warrant
either the investment or the resources: "The bottom line is that
the number of candidates for [nuclear genome transfer]
treatment is quite small, with estimates for the number in the
[United Kingdom] ranging from several dozen to several score." 3 4 9
Similarly, "[i]t is estimated that one out of 4,000 births in the
United States results in a child with mitochondrial disease,
although the true prevalence is unknown."" Based on these levels
of incidence, some commentators argue that investment in MRT
"comes at the opportunity cost of researching treatment for
mitochondrial disease that would benefit actual, living disease
344. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 1-2.
345. Id. at 2.
346. Id. at 1.
347. Id.
348. Id.
349. Cussins & Lowthrop, supra note 302, at 79.
350. Tina Rulli, What is the Value of Three-Parent IM, 46 HASTING CTR. REP. 38, 39
(2016).
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sufferers.""' The argument follows that, rather than use assets on
cycles of IVF, "[t]he National Institutes of Health could take a
strong and important stance in developing its funding agenda by
asserting that our medical dollars could be better spent
elsewhere." 3 5 2 Similarly, there are those who argue that MRT only
benefits those with money, those able to afford the time
commitment necessary, and those with expensive insurance
coverage.5 Classes are distinguishable because of what can be
afforded by the privileged few. As a result, because we rely on
technology to correct human imperfections, we create "a society
that becomes more technified and where what we consider makes
us human is lost." 3 5 4
However, other commentators emphasize an individual
person's right to a genetically connected child, and that class has
nothing to do with it. The argument is that any prohibition or
restriction placed upon MRT "would unduly infringe on [an
individual's] reproductive freedoms," 5 5 including the right to a
genetically connected child free from disease. 5 Reproductive
freedom "recognises the interests of individuals in deciding for
themselves what happens to their bodies," including genetic
affinity.35 ' It is irrelevant whether an individual may afford it or
not. An element within reproductive freedom is the individual's
right to a genetically connected child who is also free from serious
disease: "Generally, social trends in the use of assisted
reproductive technology (ART) support the argument that many
prospective parents see value in having genetically related
children, although many who pursue ART place greater
importance on having children regardless of their genetic
relation. "5 Overall, individuals pursuing greater availability of
351. Id.; see also Ezekiel J. Emanuel et al., What Makes Clinical Research Ethical?, 283
JAMA 2701, 2703 (2000).
352. Rulli, supra note 350, at 670.
353. MITOCHONDRIAL REPlACEMENT TECHNIQUES, supra note 43, at 82-83.
354. Id. at 93.
355. Schaefer & Labude, supra note 6, at 1579; see also MITOCHONDRIAL REPLACEMENT
TECHNIQUES, supra note 43, at 86 (discussing the positive right of adults to avail
themselves of new reproductive technologies). But see Rulli, supra note 350, at 46.
356. See Schaefer & Labude, supra note 6, at 1578.
357. Id. at 1579.
358. M[TOCHONDRIAIL REPLACEMENT TECHNIQUES, supra note 43, at 82 ("Having a
child genetically related to both prospective parents may be part of one's conception of
traditional family formation.").
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MRT today-and added genome editing tomorrow-argue that
they are entitled to current and expanding reproductive
freedoms,35 9 that science can and should create a society with
significantly greater freedom from disease,36 0 and that they are
entitled as a matter of individual reproductive liberty, in reference
to MRT, to genetically related procreations. 3 6'
Because a human embryo is involved, there are legislative
considerations at both the federal and state levels. Any emphasis
on transparency and engagement among different societal points
of view begins with an acknowledgement that the human genome
possesses an "inherent dignity" because of its human potential,6 2
a dignity warranting protection at the state, national, and
international level.36 3 However, there are different views as to the
level of dignity warranted. There are those who argue that humans
should not "play God" by altering human genomes, especially
when initiating germline modification. 36 4 Not all share this point
359. See ERIN NELSON, LAW, POLICY AND REPRODUCrHVE AUTONOMY 353 (2013); see
also, A.L. Bredenoord et. al., Ooplasmic and Nuclear Transfer to Prevent Mitochondrial DNA
Disorders: Conceptual and Normative Issues, 14 HUM. REPROD. UPDATE 669 (2008).
360. HUMAN GENOME EDITING, supra note 27, at 181 ("Basic laboratory research
applying genome-editing methods to human cells, tissues, germline cells, and embryos
holds promise for improving understanding of normal human biology, including
furthering knowledge of human fertility, reproduction, and development, as well as
providing deeper understanding of disease and establishing new approaches to
treatment").
361. See Maggie Kirkman, Being a 'Real' Mum: Motherhood Through Donated Eggs and
Embyos, 31 WOMEN'S STUD. INT'L FORUM 241 (2008); MITOCHONDRIAL REPLACEMENT
TECHNIQUES, supra note 43, at 45, 82.
362. See generally G.A. Res. 217 (III) A, U.N. Declaration of Human Rights, Art. 1
(Dec. 10, 1948) ("All human beings are born free and equal in dignity and rights."); G.A.
Res. 44/25, Convention on the Rights of the Child (Nov. 20, 1989) (emphasizing health
care and sanitation); G.A. Res. 3447 (XXX), Declaration on the Rights of Disabled
Persons (Dec. 9, 1975) (emphasizing respect for persons with disabilities as being
participants in diversity and humanity).
363. See Public Hearings; Request for Comments-Draft Guidelines Relating to the Regulation
of Human Cells, Tissues or Cellular or Tissue-Based Products, U.S. FOOD & DRUG ADMIN.
(2016) http://www.fda.gov/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsC
onferences/ucm462125.htm; Miriam Seifter, States, Agencies, and Legitimacy, 67 VAND. L.
REV. 443 (2014).
364. See, e.g., HUMAN GENOME EDITING, supra note 27, at 112 ("failing to appreciate
the importance of the natural world, and a lack of humility about our wisdom and powers
of control when altering that world or the people within it"); id. at 124 ("humans lack a
god-like omniscience"); id. at 155 ("lead to a new theology of science"); MITOCHONDRIAL
REPLACEMENT TECHNIQUES, supra note 43, at 91 ("Overall, the metaphor 'playing God'
itself is too vague and indeterminate to guide ... without additional premises and
arguments."); HUMAN EMBRYO RESEARCH PANEL, supra nota 40, at xv ("To many, such
research appears to represent a tampering with the natural order in unacceptable ways.").
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of view. Although it is important to recognize the depth and
diversity of views among many in American society regarding
religion and ethics, "the metaphor 'playing God' itself is too vague
and indeterminate to guide such judgements without additional
premises and arguments."' Still others argue, on a more secular
level, that a child born as a result of MRT or genome editing has
not consented to the scientific procedure,36 6 which burdens any
child-or future generations of children-with decisions made by
parents. There are those who argue that this is contrary to doing
what is in the best interest of the child.67 However, any assertion
that all actions must conform to the best interest of the child, at
least in the context of federal and state law, fails to take into
consideration that a parent is always presumed to act in the best
interest of his or her child. 6 ' Only actual clear and convincing
evidence to the contrary may rebut this presumption.3 6 9
In addition to the potential risk associated with the best
interest of a child is the arguable promotion of the dignity of each
human genome. Not all agree on the existence of a duty towards
the human genome, but it reasonable to include this
consideration in the balancing of risk and benefits framed by the
Belmont Report.3 70 The 1979 Belmont Report of the National
Commission for the Protection of Human Subjects in Biomedical
and Behavioral Research 71 was the first public national body to
shape bioethics policy in the United States.3 72 It was formed in the
365. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 91. But see 2
CATECHISM OF THE CATHOLIC CHURCH, para. 2274 (2d ed. 2000).
366. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 138--39. But see
HUMAN GENOME EDITING, supra note 27, at 111-13 (discussing that failure to obtain
consent from a minor is not an obstacle to the use of MRT).
367. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 116, 126. But see
HUMAN EMBRYO RESEARCH PANEL, supra note 40, at xii ("Given the conclusions the Panel
reached about the moral status of the preimplantation embryo, it concludes that the
health needs of women, children, and men must be given priority.").
368. See, e.g., Troxcl v. Granville, 530 U.S. 57 (2000) (holding that a child's parent has
a fundamental right to act on behalf of a child under the Fourteenth Amendment of the
U.S. Constitution).
369. See Santosky v. Kramer, 455 U.S. 745, 747-48 (1982).
370. See THE NAT'L COMM'N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL &
BEHAVIORAL RESEARCH, THE BELMONT REPORT (1979), https://www.hhs.gov/ohrp/r
egulations-and-policy/belmont-report/index.html [hereinafter "NAT'L COMM'N FOR THE
PROT. OF HUMAN SUBJECTS"].
371. Id.
372. Former Bioethics Commissions, GEO. U., https://biocthicsarchive.georgetown.edu/
pcbe/reports/pastcommissions (last visited Mar. 22, 2019).
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aftermath of the Tuskegee Experiment, a racial scandal, and the
Commission was a part of the United States Department of Health,
Education, and Welfare until 1978.1' The Report concludes that
scientific research involving human subjects should focus on three
principals: first, avoid the infliction of harm; second, accept a duty
of beneficence; and third, maintain a commitment to justice.3 74
These three principals serve as the basis of judgement for
evaluators seeking to "ensur[e] a reasonable balance between risk
and hoped-for benefits, to the individual and to society, and on
ensuring that both risks and benefits are equally shared." 7 ' The
real test of these three principles occurs when they can
accommodate the rapidly expanding array of scientific
opportunities, the realities of off-label use, international
involvement, and the lure of profits and acclaim. These factors
contribute to the risk to human genomes and to society at large.
Another element in balancing risk against benefit is what
has come to be termed "scientific optimism." It is arguable that
optimism, rather than fear, of scientific progress developed as a
result of the European Enlightenment, emphasizing reason and
individuality rather than corporate tradition.3 7 1 One author
characterizes its impact thusly: "Today, knowledge and technology
are breaking up the natural forms ... And whereas [previously]
man considered himself a part or a 'member' of nature, the
feeling today is that he can 'handle' it in unlimited freedom,
bending it to his will for prosperity or destruction."' The 1994
Report of the Human Embryo Research Panel captures the
optimism of what is scientifically possible: "The promise of human
benefit from research is significant, carrying great potential
benefit to infertile couples, families with genetic conditions, and
individuals and families in need of effective therapies for a variety
of diseases."" Buttressed by global media, incessant scientific
changes, secularization, and greater individuality, larger segments
of the global population are willing to accept what seems new and
better with a sense of optimism.
373. See NAT'L COMM'N FOR THE PROT. OF HUMAN SUBJECTS, supra note 370.
374. Id.
375. HUMAN GENOME EDITING, supra note 27, at 32.
376. ROMANO GUARDINI, THE END OF THE MODERN WORLD 188 (Joseph Thernan &
Herbert Burke trans., ISI Books 1998) (1956).
377. Id.
378. HUMAN EMBRYO RESEARCH PANEL, supra nota 40, at 65.
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Nonetheless, not all share in the benefits of scientific
optimism equally. It is arguable that scientific advances accentuate
economic social inequality; the wealthier can afford to have
healthier babies, smarter babies, even designer babies.379 An
optimistic perception may provide the milieu for allowing human
germline editing, yet efforts to eradicate disease may propel
scientist down "a slippery slope" sending us "toward less
compelling or even antisocial uses,"sso even a form of eugenics.
Current restrictions on germline modification illustrate the belief
that science is suspicious that "there are some genetic alterations
that are insufficiently justified, too risky, or too socially disruptive
to be pursued at this time."381 In spite of these concerns and
competing views regarding their potential dangers, the fact
remains that there is evidence that germline modification already
exists. 38 2 Any suspicions are balanced against current scientific
optimism, which provides assurance that " [g] enome editing holds
great promise for preventing, ameliorating, or eliminating many
human diseases and conditions." 8
Finally, another policy consideration is the transnational
aspect of modern science. The experiences of international
human genome research make irrelevant any restrictions imposed
by the United States. These would be inapplicable in foreign
countries. Furthermore, for those able to afford any desired
medical procedure available in a foreign country, "medical
tourism" or safe-haven options permit .newer, faster, and more
accommodating options in permissive jurisdictions.3 "4 The most
notable illustration of this occurred in Mexico when the first MRT
baby was born there April 6, 2016, resulting from the genetic
379. See id. at 56; see also Criteria for IRB Approval of Research, 45 C.F.R. §
46.111(a)(2) (2018); HUMAN GENOME EDITING, supra note 27, at 127-28;
MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 95-97.
380. HUMAN GENOME EDITING, supra note 27, at 129; see also DAVID PLOTZ/, THE
GENIUS FACTORY: THE CURIOUS HISTORY OF THE NOBEL PRIZE SPERM BANK (2006);
Edward Lanphier & Fyodor Urnov, Don't Edit the Human Germ Line, 519 NATURE 410
(2015).
381. HUMAN GENOME EDITING, supra note 27, at 181.
382. Rob Stein, New U.S. Experiments Aim to Create Gene-Edited Human Embryos, NPR
(Feb. 1, 2019, 5:00 AM), https://www.npr.org/sections/healh-shots/ 2 019/02/01/689
623550/new-u-s-experimens-aim-to-creae-genc-cdited-human-cmbryos.
383. HUMAN GENOME EDITING, supra note 27, at 59.
384. Rosa Castro, The Next Frontier in Reproductive Tourism? Gene Modification,
CONVERSATION (Nov. 17, 2016, 10:34 PM), https://theconversation.com/the-next-front
icr-in-reproductive-tourism-genetic-modification- 6 7 132.
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material of three different people." This was the first known baby
born as a result of the MRT procedure."' However, the birth is
illustrative of the international application of ARTs. Furthermore,
"some reports suggest that there has been successful use of three-
parent IVF in Ukraine and that efforts are now underway to
commercialise the procedure in Mexico.", 8 7 So too, the British
Parliament legalized MRT;" however, it currently remains
banned in much of the world, evidencing both geographic
disparity and opportunity among scientific discoveries.
International organizations seek to monitor developments
in different countries, but their efforts are largely ineffective. For
example, at a 2015 International Summit convened by the science
and medicine academies of the United States, the United
Kingdom, and China, the assembled scientists called for a pause of
some undefined duration in any attempt at heritable genome
editing."' Rather than banning the science of human genome
editing, the focus at the international level appears to be on
understanding the evolving views of international counterparts,
illustrated by such groups as the International Pharmaceutical
Regulators' Forum.9 o The emphasis is on bringing on board the
widest possible diversity of actors that would not normally interact
with each other, on matters of science and technology.3 9 ' But
admittedly, at play during discussion are unique historical,
385. Daniel Green, Note, Assessing Parental Rights for Children with Genetic Materialfrom
Three Parents, 19 MINN.J.L. ScI. & TECH. 251, 251 (2018).
386. Id.
387. Schaefer & Labude, supra note 6, at 1577; see also Marni J. Falk et al.,
Mitochondrial Replacement Techniques-Implications for the Clinical Community, 374 NEW ENG.
J. MED. 1103 (2016).
388. Gretchen Vogel & Erik Stokstad, UK. Parliament Approves Controversial Three-
Parent Mitochondrial Gene Therapy, SCIENCE (Feb. 3, 2015, 2:00 PM), https://www.scie
ncemag.org/news/2015/02/uk-parliament-approves-controversial-three-parent-mitochon
drial-gene-therapy?r3f_986=.
389. See THE NAT'L ACADS. OF Scis., ENG'G, & MED., INTERNATIONAL SUMMIT ON
HUMAN GENE EDITING: A GLOBAL DISCUSSION 1 (2015).
390. HUMAN GENOME EDITING, supra note 27, at 57; see also Robert M. Califf & Ritu
Nalubola, FDA's Science-Based Approach to Genome Edited Products, U.S. FOOD & DRUG
ADMIN. (Jan. 18, 2017), http://wayback.archive-it.org/8521/20180925214104/https://b
logs.fda.gov/fdavoice/index.php/2017/01/fdas-science-based-approach-to-genome-edite
d-products; R. Alta Charo, The Legal and Regulatory Context for Human Gene Editing, ISSUES
IN SCI. & TECH. (2016), https://issues.org/the-legal-and-regulaory-context-for-human-gen
e-editing.
391. Voices, ECSITE, https://www.ecsite.eu/activities-and-services/projects/voices (last
visited Mar. 22, 2019).
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cultural, and economic factors involved with only the hope for
identifying common ground on specific substantive or technical
aspects upon which to produce learning benefits.' In the
meantime, funded by independent private resources, research
continues, subject only to the possibility of international
opprobrium upon any scientific announcement.
The United States offers its own public policy guidelines
pertaining to MRT."' In its 2016 report, the National Academies
of Sciences utilized a consensus derived from a diverse group of
experts on the ethical, social, and policy issues at the core of MRT
and concluded that:
The desire of prospective parents to have children
who are at significantly reduced risk of manifesting
serious mtDNA disease and with whom they have an
nDNA connection is justifiable, and clinical
research on the use of MRT could be permitted
within limits. These limits would be focused on
protecting the health and well-being of the children
who would be born as a result of MRT."'
This conclusion was in response to a request made by the
FDA and the Institute of Medicine of the National Academies of
Sciences, Engineering, and Medicine. A committee was formed to
consider MRT and particularly, whether the ethical, social, and
policy issues involved preclude the FDA from moving forward with
consideration of MRT and clinical investigation.3 93 The committee
emphasized the need for transparency, public and patient
engagement, transnational partnership, data quality, limitations to
women with a compelling medical need, and long-term follow-
up.39 6 Interestingly, the public policy espoused forms the basis for
the regulations that follow.
392. See Xiaomei Zhai et al., No Ethical Divide Between China and the West in Human
Embryo Research, 16 DEVELOPING WORLD BIOETHICS 116, 120 (2016).
393. MITOCHONDRIAL. REPLACEMENT TECHNIQUES, supra note 43, at 7.
394. Id. at 87.
395. Id. at 149.
396. Id. at 142-44.
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iii. Regulation
a. FDA Process
If clinical research on MRT were to proceed in the United
States it would be subject to "a complex landscape of state and
federal laws and regulations," with another level of regulation
awaiting at the transnational level."' For background, currently
"[t]wenty-nine countries prohibit germline modification; the
salient laws or regulations of 10 more countries, including the
United States, are either ambiguous or would restrict but not fully
prohibit it."3 9 8 In the United Kingdom, reproductive biomedicine
is controlled pursuant to the Human Fertilisation and Embryology
Act of 1990.'9' The British legislation controls research at three
levels: first, through statutory provisions that distinguish those
things that are prohibited absolutely (and subject to criminal
penalties); second, those things that are permissible under
licenses issued by the licensing regime that permits the Human
Fertilisation and Embryology Authority to determine what
licensable activities may be carried out, by whom, and in what
circumstances; and third, through the HFEA's oversight of fertility
clinics, which ensures that the licensable activities are carried out
in accordance with license conditions and in conformity with the
HFEA's statutory Code of Practice.40 0 Interestingly, and in sharp
contrast to gender equality and individual liberties within
American jurisprudence, is HFEA's stipulation for women not to
"be provided with treatment services unless account has been
taken of the welfare of any child who may be born as a result of
the [fertilization] treatment (including the need of that child for
supportive parenting), and of any other child who may be affected
by the birth."401
However, the legal regulatory process in the United States
is more fragmented. At the federal level, similar to human
genome editing, the FDA would regulate MRT under its authority
to regulate any "human cells or tissues that are intended for
397. Id. at 59.
398. Id. at 63.
399. NUFFIELD COUNCIL ON BIOETHICS, supra note 14, at 101-02.
400. Id. at 105.
401. Id. at 106 (citing Human Fertilisation and Embryology Act 1990 c. 37 § 13(5)
(UK) (as amended)).
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implantation ... into a human." 2 "FDA does not regulate MRT
as a technique per se, but rather the 'product' that is considered a
drug and/or biologic-in this case, the manipulated oocytes or
zygotes." 403 Regulating "MRT would likely involve the same
statutes and regulations that apply to IVF, PGD, preimplantation
genetic screening (PGS), and cloning." 4 Any approval of an
Investigational New Drug Application by the FDA would require
first, respect for the moral status of a human embryo.40 Second,
clinics need to employ skilled technicians with expertise in micro-
manipulations of human gametes and/or embryos.406
Currently, federal funding for MRT research in the United
States would be prohibited because of Congressional legislative
restrictions against funding research on human embryos.m7
However, there are those who argue that an exemption is
warranted in the treatment of selected, well-studied monogenic
diseases." If there were an exemption to allow for federal funding
of MRT clinical trials, the process would commence with an IND
application and, if approved by the FDA, clinical trials in humans
402. 21 C.F.R. § 1271.3(d) (2018); see also FDA Regulation of Human Cells, Tissues, and
Cellular and Tissue-Based Products (HCT/P's) Product List, U.S. FOOD & DRUG ADMIN.,
http://www.fda.gov/BiologicsBloodVaccines/TissueTissuProducLs/Regulationoffissues
/ucml50485.htm (last updated Feb. 2, 2018); Letter to Sponsors/Researchers - Human Cells
Used in Therapy Involving the Transfer of Genetic Material by Means Other than the Union of
Gamete Nuclei, U.S. FOOD & DRUG ADMIN., https://wayback.archive-it.org/7993/201
70404210748/https:/www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm105 8 52
.htm (last updated May 6, 2009); Therapeutic Cloning and Genome Modification, U.S. FOOD &
DRUG ADMIN., https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts
/ucm2007205.htm (last updated Mar. 16, 2018).
403. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 65.
404. Id. at 60.
405. See JOHN T. NOONAN, JR., ET AL., THE MORALITY OF ABORTION: LEGAL AND
HISTORICAL. PERSPECTIVES 1-3 (John T. Noonan, Jr., et al. eds., 1970); MARY WARNOCK, A
QUESTION OF LIFE: THE WARNOCK REPORT ON HUMAN FERTILISATION AND EMBRYOLOGY
1-3 (1984); HUMAN EMBRYO RESEARCH PANEL, supra nota 40, at xi; Robert P. George &
Patrick Lee, Embryonic Human Persons: Talking Point on Morality and Human Embryo
Research, 10 EMBO REPORTS 301, 302 (2009).
406. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 121-22.
407. See 114 CONG. REC. H9434, 9445 (daily ed. Dec. 17, 2015) ("None of the funds
made available ... may be used ... in research in which a human embryo is intentionally
created or modified to include a heritable genetic modification.") But even though
funding for the research is prohibited, there is no such prohibition on the research itself.
MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 64.
408. See, e.g., Seitz, supra note 7, at 89-90 ("It is estimated that monogenic diseases
affect up to 13 million people in the U.S., causing nearly one-fifth of infant mortality.
Many of the thousands of monogenic diseases lead to severe physiological impairment or
early death.").
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would begin. If the application is authorized, clinical
investigations may commence and, if successful, a Biologic License
Application or a New Drug Application may be submitted. Then, if
the FDA considers that the product is safe and effective-and
benefits outweigh the risks-the application is approved and the
product may be marketed in the United States.
Approval by the FDA would employ an oversight and IRB
risks and benefits review. "Any institution that receives federal
funds for research involving human subjects must establish an
IRB, and all such research performed at the institution must be
reviewed by the IRB, regardless of its source of funding." " IRB
review would involve balancing the risks and benefits for five
potential parties affected by MRT. They are: (1) individuals who
provide gametes (oocytes or sperm) that are then used to
construct embryos; (2) any intended parent or parents; (3)
gestational carriers if one is needed; (4) any child born as a result
of MRT; and (5) any potential future offspring of female children
born as a result of MRT.410 Each applicable party would need to
provide informed and voluntary consent to participating in the
process."' When intended parents provide consent to any MRT
procedure, they would, in essence, be consenting on behalf of any
future children."' Also, there would have to be post-approval
oversight to ensure that the National Academies of Sciences
primary consideration is protected, that being assessing risk and
benefit to the health and well-being of future children.4 1 3
b. Post-Approval Oversight
In its 2016 report on MRT, the National Academies of
Sciences, Engineering, and Medicine made several
recommendations for oversight of the procedure through
emphasis on transparency, public and private engagement,
sharing of information with domestic and foreign researchers and
regulatory agencies, evaluation of high-quality data, and an
409. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 68.
410. Id. at 115, 131-32.
411. LINDA ALDOORY ET AL., BEST PRACTICES AND NEW MODELS OF HEALTH LITERACY
FOR INFORMED CONSENT REGULATIONS ON HEALTH LITERATE COMMUNICATIONS 26
(2014).
412. MITOCHONDRIAL REPLACEMENT TECHNIQUES, supra note 43, at 138.
413. Glenn Cohen, Circumvention Medical Tourism and Cutting Edge Medicine: The Case
ofMitochcndrial Replacement Therapy, 25 IND.J. GLOBAL LEGAL STUD. 439, 445-46 (2018).
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incremental approach to monitor effects and commitment to
long-term follow-up.4 1 4 As part of this follow-up the FDA has a Risk
Evaluation and Mitigation Strategy program to monitor
postapproval developments.4 1 5 The Food and Drug Administration
Amendments Act of 2007 provides the FDA with the authority to
ensure that a product approved by the FDA is then used in a
postapproval manner such that its benefits outweigh its risks. 1 '
The postapproval review applies to on or off-label use." 7
There are a few examples where government regulation
bans certain scientific research. To date, states and the federal
government have banned cloning of human beings,4 18 and human
eugenics has been widely condemned.4 19 Off-label use of the
human growth hormone has been made a criminal offense, but
" [p] ostmarket use may also encompass uses that go beyond the
indications for which a therapy was approved." 2 ' Thus, with few
exceptions, off-label use in clinical care is entirely legal and has
become a common practice among physicians, which could apply
to gene editing once it is approved. Physicians "are regulated at
the state level by their licensing and disciplinary bodies, [and] may
be limited by availability of patients' insurance coverage for novel
interventions."4 2 1 Physicians are also constrained by the prospect
of tort liability for malpractice, should they be deemed reckless of
negligent.422
Regulation at the state level varies:
414. See J.B. Appleby, The Ethical Challenges of the Clinical Introduction of Mitochondrial
Replacement Techniques, 18 MED., HEALTH CARE, & PHIL. 501 (2015).
415. Risk Evaluation and Mitigation Strategies (REMS), U.S. FOOD & DRUG ADMIN.,
https://www.fda.gov/Drugs/DrugSafety/REMS/defaulLhtm (last visited Mar. 22, 2019).
416. Id.
417. Understanding Unapproved Use of Approved Drugs "Off Label", U.S. FOOD & DRUG
ADMIN., https://www.fda.gov/forpatiens/other/offlabel/default.htm (last visited Mar.
22, 2019).
418. CAL. HEALTH & SAFETY CODE §§ 24185-87 (1998); Memorandum from the
Office of the Press Secretary for the Heads of Executive Departments and Agencies (Mar.
4, 1997) (on file with the White House); Cloning Californians? Report of the California
Advisory Committee on Human Cloning, 55 HASTINGS L.J. 1143 (2002).
419. Stephanie Hennette-Vauchez, A Human Dignitas? Remnants of the Ancient Legal
Concept of Contemporary DignityJurisprudence, 9 INT'LJ. CONST. L. 32 (2011).
420. HUMAN GENOME EDITING, supra note 27, at 36.
421. Id.
422. See, e.g., Bos. Coll. Law Review Staff, supra note 313.
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California, for example, has been funding embryo
research and embryonic stem cell research for a
decade using funds from a state bond issued during
the years when federal funding was limited to a
small number of older embryonic stem cell lines.
Connecticut, Maryland, New Jersey, and New York
also created funds for research that could not be
federally funded.42 3
Additionally, state licensing boards, which monitor physicians, vary
widely in their stringency. Any practitioner, however, could be
disciplined for use of MRT-on label or off-label-that was
inappropriate for the patient or that was provided prior to
properly obtaining voluntary consent.42 4 Interestingly, in its 2018
report on genome editing and human reproduction, the British
Nuffield Council on Bioethics reported that a policy of good
practice is "very well embedded" in the field of human
reproduction due in part to high professional standards and
among scientists and practitioners.4 25 The Council also suggests
that good practices result from public engagement and "the hawk-
like media attention given to issues in reproductive
biomedicine." 2 6 Likewise, insurance coverage and its threat of
denial of coverage, is often a stringent restraint on off-label use by
physicians.4 27 That, and the prospect of tort liability.4 2 8
Amid these competing arguments, review panels, agencies,
and legislatures must make decisions pertaining to funding of
laboratory research, preclinical trials, clinical trials, and potential
medical uses. And federal and state laws haltingly address
accelerating, even revolutionary, advances in medical
technology.4 29 These groups and regulatory pronouncements also
423. HUMAN GENOME EDITING, supra note 27, at 43 (citation omitted); see also State
Initiatives for Stem Cell Research, NAT'L INST. HEALTH, https://stemcells.nih.gov/resear
ch/state-research.htm (last visited Mar. 22, 2019).
424. MITOCHONDRIAt REPLACEMENT TECHNIQUES, supra note 43, at 71.
425. NUFFIELD COUNCIL ON BIOETHICS, supra note 14, at 106.
426. Id.
427. Id. at 13 n.32, 15.
428. See Bos. Coll. Law Review Staff, supra note 313, at 332-33, 335.
429. See, e.g., 42 U.S.C. § 263a-1 (2018); ARIZ. REv. STAT. ANN. § 36-2311-2313 (2018);
CAL. HEALTH & SAFETY CODE ANN. § 24185 (Decring 2012); LA. STAT. ANN. § 9:122-129
(2018); MICH. COMP. LAWS SERV. § 333.2685(1) (LexisNexis 2015); 18 PA. STAT. AND
CONS. STAT. ANN. § 3216(a) (2015); Consolidated Appropriations Act of 2016, Pub. L. No.
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are interactive with the regulatory infrastructures of other
countries. 430 Their task is made more difficult because of three
identifiable undercurrents existing in the United States today:
scientific optimism, off-label development, and international
opportunities.
c. International Oversight
As has been discussed above, genome editing exists within
a transnational community; modern technology does not permit
scientific development to be contained to a single nation.4 3 1 "The
globalisation of neoliberal capitalism has created the conditions
not only for greater possibilities of diffusion and movement of
knowledge, technology, skills, patients, tissues, data, etc., but also
their independence of movement." 4  Hence, while the United
States may prohibit funding for embryonic research and impose a
lengthy regulatory procedure prior to approval of any products or
procedures, other developed countries may permit genome
editing or mitochondrial replacement resulting in "designer
babies" or heritable modifications. For example, MRT is now legal
in Great Britain."' In China, which is more prolific in research on
human embryos and genome editing, biomedical research is
governed by the National Health and Family Planning
Commission.4 34 Although Chinese law bans gene manipulation on
human gametes, zygotes, and embryos for the purpose of
reproduction,43 5 "reproductive services such as sex selection and
surrogacy, which are technically illegal in China, are nevertheless
available in practice." 43 6 The fact that a Chinese scientist, working
at the Southern University of Science and Technology in
Shenzhen, China, was able to announce the birth of two genome-
edited babies at the start of the 2018 Second International Summit
114-113, 2015 129 Stat. 2283, 2617, 2650; 21 C.F.R. §§ 1271.1, 1271.3 (2016); 45 C.F.R. §
46.204(d) (2003).
430. HUMAN GENOME EDITING, supra note 27, at 57.
431. Id.
432. NUFFIELD COUNCIL ON BIOETHICS, supra note 14, at 113.
433. Kate Kelland, Britain Becomes First Nation to Legalize Three-Parent Babies, REUTERS
(Feb. 24, 2015, 4:00 PM), https://www.reuters.com/article/us-health-babics-3parent/brita
in-becomes-first-nation-to-legalize-three-pacnt-babies-idUSKBNOLS2GH2015022 4 .




2019] GENOME EDITING AND MITOCHONDRIAL REPLACEMENT 487
on Human Genome Editing, illustrates the divergence between
public regulation and private research.117
Many factors contribute to a nation's explicit or tacit
acquiescence in human genome editing procedures: first, there
are large profits to be made from a growing demand for assisted
reproductive services, hence unauthorized private clinics can
establish a clientele and practice absent government scrutiny;
second, if government oversight lacks focus and explicit direction
the cumbersome nature of regulatory bureaucracy allows for only
piecemeal enforcement of any regulations; and third, public
awareness and resulting public debate prompt more efficient
regulatory review of practices and products, but their absence
permits tacit permissiveness.4 3 8 As was summarize by the Nuffield
Council on Bioethics, " [u] nlike the US, where debate is open and
fierce, if lacking in focus, or like the UK, where debate tends to be
more coherently oriented towards regulatory or parliamentary
activities," there exists "little public and media debate in China
that allows space for diverse stakeholders and points of view, and
no evidence of public engagement initiatives, either on the part of
government-related bodies or civil societal organisations." 439
Fourth, the rapidity of human scientific biomedical developments,
coupled with increasing scientific optimism resulting in part from
this rapidity, blunts the immediacy of addressing societal concerns
over human genome editing."# Fifth, the complexity of the
437. See Rob Stein, Facing Backlash, Chinese Scientist Defends Gene-Editing Research on
Babies, NPR (Nov. 28, 2018, 2:14 AM), https://www.npr.org/sectionns/health-shots/
2018/11/28/671 3 7 5070/facing-backlash-chinese-scientist-defends-gene-editing-reseaar
ch-on-babies. China immediately halted his experiments after the announcement he
altered the DNA of twin girls and unveiled draft regulations on gene editing and other
biomedical practices. Yanan Wang & Fu Ting, China Drafts Rules on Biotech After Gene-
Editing Scandal, AP NEWS (Feb. 27, 2019), https://www.apnews.com/47aa8ffa382c4a
el9eb6cc202f93ddf8.
438. See Donna Rosato, How High-Tech Baby Making Fuels the Infertility Market Boom,
MONEY (July 9, 2014), http://money.com/mony/2955345/high-tech-baby-making-is-fuel
ing-a-market-boom; Nick Malyshev, The Evolution ofRegulatory Policy in OECD Countries 17-
19, OECD, https://www.oced.org/gov/regulatory-policy/41882845.pdf (last visited on
Mar. 22, 2019) (explaining the importance of regulatory oversight that is well-organized
and monitored and the necessity of an open process to the public as a way to improve
regulatory review).
439. NUFFIELD COUNCILON BIOETHICS, supra note 14, at 112.
440. See Genome Editing: What Are the Ethical Concerns About Genome Editing?, NAT'L
HUM. GENOME INST. (Aug. 3, 2017), https://www.genome.gov/27569225/what-are-the-eth
ical-concerns-about-genome-editing.
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scientific terminology and procedures blunt public participation
and obfuscate transparency."
Only one international document explicitly addresses
heritable genetic modification, the 1997 Oviedo Convention.2
Not all member states of the Council of Europe have ratified the
Oviedo Convention, including the United Kingdom, but the
principles espoused in the Convention find resonance in foreign
research reports on the subject of genome editing."  The
Convention and corresponding reports suggest, first, that any
human genome editing should serve human health, not physical
appearance or gender selection, and second, modification may
not introduce changes that can be passed on to future
generations.44
Frustration with current international regulatory and
governance protocols concerning clinical use of heritable
germline editing was illustrated at the Second International
Summit on Human Genome Editing convened in Hong Kong,
China in November 2018. Confronted with the announcement of
"an unexpected and deeply disturbing claim that human embryos
had been edited and implanted, resulting in a pregnancy and the
birth of twins,"" the Organizing Committee "suggest[ed] that it
[was] time to define a rigorous, responsible transnational pathway
toward such [clinical] trials [of germline editing]." ' This
announcement was both an admission that genome editing was a
reality and that it was time to establish a clear pathway to address it
or it "could produce unintended harmful effects for not just an
individual but also for that individual's descendants."7
441. See Plain Language: A Promising Strategy for Clearly Communicating Health
Information and Improving Health Literacy, U.S. DEP'T HEALTH & HUM. SERVS., https://
health.gov/communication/licracy/plainlanguage/PlainLanguage.htm (last visited on
Mar. 22, 2019) (discussing the importance of plain language regarding scientific
terminology and patient involvement).
442. NUFFIELD COUNCIL ON BIOETHICS, supra note 14, at 115.
443. Council of Europe: The Oviedo Convention's Applications and Challenges, ALLIANCE
VITA (Oct. 27, 2017), https://www.alliancevita.org/en/2017/10/councilf-europe-thc-ov
iedo-conventions-applications-and-challenges.
444. See Ismini Kriari-Catranis, The Convention for the Protection of Human Rights and
Dignity of the Human Being with Regard to the Application of Biology and Medicine: Convention
on Human Rights and Biomedicine, 12 EUBIOS J. ASIAN & INT'L BIOETHICS 90 (2002)
(discussing the principles of the Oviedo Convention).
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Specifically, the Committee proposes an ongoing International
Forum that will foster broad public dialogue, develop strategies for
increasing equitable access by members of the underserved
populations, speed the development of regulatory science, provide
a clearinghouse for information on regulatory options, develop
common regulatory standards, and enhance coordination of
research and clinical applications through an international
registry of planned and ongoing experiments.' This is quite an
agenda, but it illustrates that the longer a pathway is delayed, the
more it will take to define its parameters.
The alarm over the reality of human genome editing,
including its effects upon the human germline, is significant. Yet
because of the individuality of nations and the plethora of private
and semi-private elements within each nation, any international
forum will serve an advisory role and nothing more. The inability
of the international community to curtail nuclear arms or
international terrorism is illustrative of this. Today, the best that
can be achieved is for each nation to take responsibility to
recognize the immediacy of human genome editing and, as the
Summit suggests, establish a pathway towards a consensus of
agreement rather than default.
III. CONCLUSION
Plotting a pathway for the future begins with knowing the
past, but the past does not extend far. It was in 1953 that James
Watson and Francis Crick discovered the double helix, the twisted-
ladder structure of deoxyribonucleic acid, better known as DNA.'
This was the beginning. The paired structure of DNA, which
encodes the genome, enables the copying mechanism that allows
448. Id. On February 21, 2019, the World Health Organization established a
committee of eighteen experts to examine the scientific, ethical, social, and legal
challenges associated with human genome editing so as to make recomendations.
Preetika Rana, WHO Reacts to Chinese Gene-Edited Tw1ins with Plan for Global Guidelines,
WALL ST. J. (Feb. 21, 2019), https://www.wsj.com/articles/who-reacts-to-chinese-gene-
edited-twins-with-plan-for-global-guidelines11550736189?mod=searchresults&page=1&pos
=1.
449. The Francis Crick Papers: The Discovery of the Double Helix, 1951-1953, U. S. NAT'L
LIBR. MED., https://profiles.nlm.nih.gov/SC/Views/Exhibit/narrative/doublehelix.html
(last visited Mar. 22, 2019).
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the genome to be transmitted from generation to generation.45
The genome of each individual is composed of approximately
one-half provided by the biological mother and the other half
provided by the biological father.4 5 ' Genetic materials from each
of the parents is transmitted during reproduction, resulting in the
unique genome of the offspring of the two parents. Once formed,
the genome contains the full sequence of genetic material (DNA
in humans) in an organism or species.4M
Today, as a result of recent scientific research and
developments it is possible to edit a genome, that is, to "modify[]
an embryo or the cells from which it is formed by techniques of
genome editing, in order to ensure that a future child has the
selected genetic variants.""' When we speak of genome editing we
mean the process by which the genome sequence is changed
through intervention of a DNA break or other DNA
modification.4 5 4 Because of modern scientific ability to edit the
genome, science began the study and diagram of the human
genome variants, by which it could decipher the array of human
characteristics, the propensities for disease in any given embryo,
and how an individual may live in an environment that may
precipitate reactions to various environmental factors.45 5
Genome editing would not be possible without parallel
developments in the science IVF.45 6 Slightly more than two
decades after the discovery of DNA in 1953, a physician in
Oldham, England, performed an IVF procedure that resulted in
450. See JAMES D. WATSON, THE DOUBLE HELIX: A PERSONAL ACCOUNT OF THE
DIScOVERY OF THE STRUCTURE OF DNA (1968); Francis C. Crick & James D. Watson,
Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid, 171 NATURE 737,
737-38 (1953).
451. NUFFIELD COUNCIL ON BIOETHICS, supra note 14, at 6.
452. Id. at 174.
453. Id. at 6.
454. HUMAN GENOME EDITING, supra note 27, at 299.
455. Id. at xi.
456. In vitro fertilization is "[a]n assisted reproduction technique in which
fertilization is accomplished outside the body.'" Id. at 301. "Clinically, lVE refers to a
procedure in assisted reproduction wherein eggs are removed from the body (often
flowing artificial stimulation of the ovaries) and mixed with sperm in a dish, or injected
with sperm in ICSI. A resulting embryo may then be transferred to a woman's uterus with
the intention of establishing a pregnancy." NUFFIELD COUNCIL ON BIOETHICS, supra note
14, at 175.
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the birth of Louise Brown in 1978.457 She is heralded as the first
child conceived in a laboratory dish rather than in a living
woman.' Since the birth of this first "test tube baby," ART has
developed rapidly, permitting both gestational and genetic
surrogacy arrangements, genetically connected births to
heretofore infertile couples, posthumous conception and
resulting births, and the banking of eggs, sperm, and embryos in
fertility clinics throughout the world." The number of IVF
procedures, and the children resulting from these procedures,
increase each year in the United States and transnationally.4 " It is
the combination of the discovery or DNA, IVF, and genome
editing that we arrive at this point.
By 2012, scientists developed a cheaper and efficient
method to edit genomes. 46 1 Currently, the best method is called
CRISPR-Cas9, and it provides scientists with the ability to cheaply
and precisely target and alter DNA in living cells.4 2 Because of this
revolutionary technology-and the more efficient ones that
follow-it is now possible to "edit" genomes comprising DNA
sequences that encode a functional product such as a protein or
RNA molecule.4 " Because of this editing process, scientists may
prevent severe debilitating disease from ever developing in babies.
This can be done through a MRT that will prevent mitochondrial
disease.' However, in addition to eliminating disease, it is also
possible to edit other genes, thereby affecting personal
appearance, gender, and other distinguishing characteristics that
precipitate the diversity heretofore characteristic of human
society." Of greater concern, editing a gene in an embryo today
may have unknown repercussions, good and bad, in generations to
follow as a result of germline editing. The scientific ability to edit
genes and precipitate germline modifications prompts concerns
457. World' First Test Tube Baby Born, HISTORY (Mar. 12, 2010), https://www.his
tory.com/this-day-in-history/worlds-first-test-tube-baby-born.
458. Id.
459. Seejudith F. Daar, Embryonic Genetics, 2 ST. LOuIS U.J. HEALTH L. & POL'Y 81, 87
(2008).
460. Id.
461. NUFFIELD COUNCIL ON BIOETHICS, supra note 14, at vii.
462. Id.
463. Id. at 174-75. The RNA transfers information from genomic DNA to the protein-
synthesis machinery of cells.
464. Id. at 75 n.248.
465. Id. at 53 n.172.
WAKE FOREST JOURNAL OF LAW & POLICY
about public policy, public interest, and public morality. 66 This
concern is illustrated in the reports from scientific groups in the
United States and international organizations and is reflected in a
statement by a group from the United Kingdom, the Nuffield
Council on Bioethics:
[We] conclude that what is important is not the
conservation or alteration of a particular range of
characteristics at the level of the genome, but rather
the potential consequences of genomic
interventions for people and the social relations in
which they stand to one another. These are
expressed not in in pursuit of uncertain outcomes,
but in the orientation towards those futures.4 67
Continuing scientific achievements, the multi-billion-dollar
pharmaceutical industry, and what has come to be termed
"medical tourism "468 accelerate the immediacy of the concern
over genome editing and mitochondrial replacement. This
immediacy is illustrated by the announcement on November 28,
2018, that a scientist in China seemingly succeeded in genetically
editing the genes of twin girls when they were embryos, but were
later born apparently healthy." 9 This is the first reported instance
of human genome editing, but it signals that the issue is no longer
academic, but real. The condemnation of the scientist's action by
the scientific community was immediate, challenging the
scientist's "rogue" action as lacking in transparency and
conformity with international norms.4 70 Various scientific
organizations throughout the world recognized that this day was
coming, hoping that calls for transparency, international
responsibility, and a coordinated approach would delay its arrival.
Now it is here. What is to happen? First, the consensus is that
science is unstoppable. This is a given. Moreover, scientific
achievements are welcomed with a sense of optimism. However,
this recognition does not alleviate responsible application of all
466. Id. at 51-53.
467. Id. at 95.
468. See, e.g., Cohen, supra note 413.
469. Stein, supra note 172.
470. On Human Genome Editing H, supra note 151.
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scientific advancements. What then should be our application
within the United States?
First, responsible public policy, based in positive law and
regulatory function, should manifest a pathway towards an
acceptable ethical and moral approach towards genome editing
and, as an element thereof, mitochondrial replacement,
formulated with contributions from all those interested in its
impact on society.
Second, the forum for developing this pathway begins with
the United States Congress. The specific goal for Congress to
consider is whether the current Dickey-Wicker Amendment is
responsive to the impact of genome editing and mitochondrial
replacement. Inasmuch as the Amendment prohibits, without
exception, it is not a responsible approach towards protecting
American current and future populations.
Third, as a regulatory approach to approval of genome
editing, an appraisal must be made of the Consolidated
Framework as to whether it adequately addresses not only current
challenges, but ones that lie on the horizon.
Fourth, it must be determined whether the regulatory
process by which the FDA regulates products that will be marketed
within the United States is sufficiently responsive to both the
benefits and risks of genome editing and mitochondrial
replacement.
Fifth, any biologic pathway established must include a
process for interaction with the transnational community of
scientists and national policy-makers.
Sixth, any pathway must include the following specific
goals:
(1) Precise risk versus benefit guidelines must be
developed with a focus on the best interest of any child born in
association with genome editing;
(2) Peer responsibility must be fostered among national
and transnational scientists to establish proper guidelines to
manage germline editing, and also to regulate international
applications of newer means to edit human germlines;
(3) Means must be established to interact with persons with
different societal backgrounds envisioning inclusion of all, social
justice, plurality, and moral persuasion;
(4) A responsible pathway must be drafted through
transparency, an engaged media, sufficient opportunity for all
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significantly interested parties to be heard, and adequate
information concerning the procedures involved; and
(5) The dignity of all human voices must be respected to
include religious, ethical, and proponents of reproductive liberties
and gender equality.
The advent of genome editing, including mitochondrial
replacement, involves several aspects never previously
encountered by human beings This is a transnational issue that
portends significant profits for pharmaceutical companies and
miraculous treatments of serious hereditary diseases that have
perpetually plagued humanity. The scientific community's
interconnectedness provides sufficient commentary to formulate
the challenges presented with abundant clarity.
However, of particular difficulty is the fact that genome
editing challenges societies to reexamine their social structure and
plurality, including its shameful historical episodes of eugenics.
Finally, the opportunity of genome editing and mitochondrial
replacement prompts an immediacy of action on the part of
governments, not to ban, condemn, or to castigate, but rather to
chart a scientific pathway by which the national and transnational
communities can balance scientific optimism with the values that
make us all human together.
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